Search Results

ClinicalTrials.
gov Search Results 04/01/2020

NCT Number Title Other Names Status Conditions Interventions Characteristics Population Sponsor/ Funder Dates Locations
Collaborators Type
1 NCT04291053 The Efficacy and Safety of Huai Title Acronym: Not yet •COVID-19 •Drug: Huaier Study Type: Enrollment: •Tongji Hospital •Other Study Start:
er in the Adjuvant Treatment of recruiting Granule Interventional 550 April 1, 2020
COVID-19 Other Ids:
TJ-IRB20200205 Phase: Age: Primary Completion:
Study Documents: •Phase 2 18 Years to 75 August 1, 2020
Years (Adult,
•Phase 3
Older Adult) Study Completion:
Study Design: September 1, 2020
Sex:
•Allocation: Randomized
All First Posted:
•Intervention Model: Parallel March 2, 2020
Assignment
•Masking: None (Open Results First Posted:
Label) No Results Posted
•Primary Purpose:
Treatment Last Update Posted:
March 17, 2020
Outcome Measures:
•Mortality rate
•Clinical status assessed
according to the official
guideline
•The differences in oxygen
intake methods
•Duration (days) of
supplemental oxygenation
mechanical ventilation
•The mean PaO2/FiO2
•Length of hospital stay
(days)
•Length of ICU stay (days)
•Pulmonary function
- Page 1 of 73 -
Collaborators Type
2 NCT04324489 DAS181 for COVID-19: Title Acronym: Recruiting •COVID-19 •Drug: DAS181 Study Type: Enrollment: •Renmin Hospital •Other Study Start: •Renmin Hospital of Wuhan
Compassionate Use Interventional 4 of Wuhan March 6, 2020 University, Wuhan, Hubei,
•Industry
Other Ids: University China
Study Documents: DAS181-SARS- Phase: Age: •Ansun Primary Completion:

CoV-2 Not Applicable 18 Years to 70 Biopharma, Inc. April 25, 2020
Years (Adult,
Study Design: Older Adult) Study Completion:
•Intervention Model: Single April 30, 2020
Group Assignment Sex:
All First Posted:
•Masking: None (Open
Label) March 27, 2020
•Primary Purpose:
Results First Posted:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•Improved clinical status
March 27, 2020
•Return to room air
•SARS-CoV-2 RNA
•Discharge
•Death
- Page 2 of 73 -
Collaborators Type
3 NCT04323228 Anti-inflammatory/Antioxidant Title Acronym: Not yet •COVID-19 •Dietary Study Type: Enrollment: •King Saud •Other Study Start:
Oral Nutrition Supplementation ONSCOVID19 recruiting Supplement: Interventional 30 University April 1, 2020
in COVID-19 oral nutrition
Other Ids: supplement Phase: Age: Primary Completion:
(ONS) enriched in
Study Documents: ONS_COVID-19 eicosapentaenoic Phase 4 18 Years to 65 October 1, 2020
acid, gamma- Years (Adult,
linolenic acid and Study Design: Older Adult) Study Completion:
antioxidants •Allocation: Randomized October 30, 2020
Sex:
•Dietary •Intervention Model: Parallel
All First Posted:
Supplement: Assignment
isocaloric/ March 26, 2020
isonutrigenous •Masking: Double
ONS (Participant, Care Provider)
•Primary Purpose: No Results Posted
Supportive Care
Last Update Posted:
Outcome Measures:
March 27, 2020
•Change from baseline
score of Nutrition
risk screening-2002
(NRS-2002) at end of the
trial
Serum ferritin level at end
of the trial
serum Interleukin-6
concentration at end of the
trial
serum C-reactive protein
concentration at end of the
trial
serum Tumor necrosis
factor-# concentration at
end of the trial
serum monocyte
chemoattractant protein 1
(MCP-1) at end of the trial
Weight at end of the trial
•Height
•Change from baseline BMI
at end of the trial
•Change from baseline mid
arm circumference at end
of the trial
•and 8 more
- Page 3 of 73 -
Collaborators Type
4 NCT04323332 Traditional Chinese Medicine for Title Acronym: Not yet •COVID-19 •Drug: Traditional Study Type: Enrollment: •Xiyuan Hospital •Other Study Start: •Hao Li, Beijing, Beijing, China
Severe COVID-19 recruiting Chinese Medicine Interventional 50 of China March 2020
Other Ids: Prescription Academy of
2020XLA015-1 Phase: Age: Chinese Medical Primary Completion:
Study Documents: Sciences
Phase 3 up to 85 Years March 2020
(Child, Adult, Older
Study Design: Adult) Study Completion:
•Allocation: Non- April 2020
Randomized Sex:
All First Posted:
•Intervention Model: Parallel
Assignment March 26, 2020
Label)
No Results Posted
•Primary Purpose:
March 26, 2020
Outcome Measures:
(days)
•CT imaging changes
•Mortality rate
•Time to Clinical
Improvement (TTCI)
•The pneumonia severity
index scores
•Time to COVID-19 nucleic
acid testing negativity in
throat swab
•Blood immune cell count
•Serum inflammatory
markers
•Erythrocyte sedimentation
rate
•and 6 more
- Page 4 of 73 -
Collaborators Type
5 NCT04325633 Efficacy of Addition of Naproxen Title Acronym: Not yet •COVID-19 •Drug: 1: Naproxen Study Type: Enrollment: •Assistance •Other Study Start:
in the Treatment of Critically ENACOVID recruiting Interventional 584 Publique - March 27, 2020
•Drug: 2: Standard
Ill Patients Hospitalized for Hôpitaux de
of care
COVID-19 Infection Other Ids: Phase: Age: Paris Primary Completion:
APHP200387 Phase 3 18 Years and older April 27, 2021
Study Documents: (Adult, Older
•Allocation: Randomized June 27, 2021
Sex:
All First Posted:
Assignment
March 27, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 27, 2020
•Mortality all causes at
day30
•Number of days alive free
of mechanical ventilation
•Number of days alive
outside
•Number of days alive
outside hospital
•Maximal changes in Sofa
score
•Time to negativation
of virus titer in the
nasopharyngeal aspirate
(NPA)
6 NCT04321421 Hyperimmune Plasma for Title Acronym: Active, not •COVID-19 •Other: Study Type: Enrollment: •Foundation •Other Study Start: •Catherine Klersy, Pavia, PV,
Critical Patients With COVID-19 COV19-PLASMA recruiting hyperimmune Interventional 49 IRCCS San March 17, 2020 Italy
plasma Matteo Hospital
Study Documents: Other Ids: Phase: Age: •OSPEDALE Primary Completion:

IRCCSSanMatteoH Not Applicable 18 Years and older CARLO May 31, 2020
(Adult, Older POMA ASST
Study Design: Adult) MANTOVA Study Completion:
•Intervention Model: Single •OSPEDALE May 31, 2020
Group Assignment Sex: MAGGIORE
All LODI First Posted:
Label) •OSPEDALE March 25, 2020
ASST
•Primary Purpose:
CREMONA Results First Posted:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•death
March 25, 2020
•time to extubation
•length of intensive care
unit stay
•time to CPAP weaning
•viral load
•immune response
- Page 5 of 73 -
Collaborators Type
7 NCT04306497 Clinical Trial on Regularity Title Acronym: Recruiting •COVID-19 •Drug: TCM Study Type: Enrollment: •Jiangsu •Industry Study Start: •Huai'an fourth people's
of TCM Syndrome and CTOROTSADTOC prescriptions Observational 340 Famous Medical March 2, 2020 Hospital, Huaian, Jiangsu,
Differentiation Treatment of Technology Co., China
COVID-19. Other Ids: Phase: Age: Ltd. Primary Completion:
JSZYJ202001 18 Years to 75 May 2020
Study Documents: Study Design: Years (Adult,
•Observational Model: Older Adult) Study Completion:
Cohort May 2020
Sex:
•Time Perspective:
Prospective All First Posted:
March 13, 2020
Outcome Measures:
•The relief / disappearance Results First Posted:
rate of main symptoms No Results Posted
•Chest CT absorption
Last Update Posted:
•Virus antigen negative
March 17, 2020
conversion rate
•Clinical effective time: the
average effective time
•The number of severe and
critical conversion cases
•Incidence of complications
•Traditional Chinese
Medicine Syndrome Score
- Page 6 of 73 -
Collaborators Type
8 NCT04287686 Recombinant Human Title Acronym: Withdrawn •COVID-19 •Drug: Recombinant Study Type: Enrollment: •The First •Other Study Start: •GCP Office of The First
Angiotensin-converting Enzyme human angiotensin- Interventional 0 Affiliated February 2020 Affiliated Hospital of
2 (rhACE2) as a Treatment for Other Ids: converting enzyme Hospital of Guangzhou Medical University,
Patients With COVID-19 GIRH-APN01 2 (rhACE2) Phase: Age: Guangzhou Primary Completion: Guangzhou, Guangdong, China
Medical
Not Applicable 18 Years to 80 University April 2020
Study Documents: Years (Adult,
•Allocation: Randomized April 2020
Sex:
All First Posted:
Assignment
February 27, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 17, 2020
•Time course of body
temperature (fever)
•Viral load over time
•P/F ratio over time
•Sequential organ failure
assessment score(SOFA
score) over time
•Pulmonary Severity Index
(PSI)
•Image examination of
chest over time
•Proportion of subjects
who progressed to critical
illness or death
•Time from first dose to
conversion to normal or
mild pneumonia
•T-lymphocyte counts over
time
•C-reactive protein levels
over time
•and 17 more
- Page 7 of 73 -
Collaborators Type
9 NCT04324996 A Phase I/II Study of Universal Title Acronym: Recruiting •COVID-19 •Biological: NK Study Type: Enrollment: •Chongqing •Other Study Start: •Chongqing Public Health
Off-the-shelf NKG2D-ACE2 cells,IL15-NK Interventional 90 Public Health March 21, 2020 Medical Center, Chongqing,
CAR-NK Cells for Therapy of Other Ids: cells,NKG2D CAR- Medical Center China
COVID-19 ChongqingPublicHMC NK cells,ACE2 Phase: Age: Primary Completion:
•Chongqing
CAR-NK
•Phase 1 18 Years and older Sidemu May 31, 2020
cells,NKG2D-ACE2
Study Documents: (Adult, Older Biotechnology
CAR-NK cells •Phase 2
Adult) Technology Study Completion:
Co.,Ltd.
Study Design: September 30, 2020
Sex:
All First Posted:
Assignment
•Masking: Quadruple Results First Posted:
(Participant, Care Provider, No Results Posted
Investigator, Outcomes
Assessor) Last Update Posted:
•Primary Purpose: March 27, 2020
Treatment
Outcome Measures:
•Clinical response
•Side effects in the
treatment group
10 NCT04329832 Hydroxychloroquine vs. Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •Intermountain •Other Study Start: •Intermountain Medical Center,
Azithromycin for Hospitalized HAHPS recruiting Hydroxychloroquine Interventional 300 Health Care, Inc. April 1, 2020 Murray, Utah, United States
Patients With Suspected or
•Drug: Azithromycin •University of •University of Utah, Salt Lake
Confirmed COVID-19 Other Ids: Phase: Age: Primary Completion:
Utah City, Utah, United States
1051355 Phase 2 18 Years and older December 31, 2020
•Allocation: Randomized December 31, 2021
Sex:
All First Posted:
Assignment
April 1, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
April 1, 2020
•COVID Ordinal Outcomes
Scale at 14 days
•Hospital-free days at 28
days (number of days
patient not in hospital)
•Ventilator-free days at
28 days (number of days
patient not on a ventilator)
•ICU-free days at 28 days
(number of days patient
not in an ICU)
•Time to a 1-point decrease
in the WHO ordinal
recovery score
- Page 8 of 73 -
Collaborators Type
11 NCT04328285 Chemoprophylaxis of SARS- Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •Centre •Other Study Start: •CHU d'Angers, Angers, France
CoV-2 Infection (COVID-19) in COVIDAXIS recruiting Hydroxychloroquine Interventional 1200 Hospitalier March 30, 2020
•Industry •AP-HP - Hôpital Bichat, Paris,
Exposed Healthcare Workers Universitaire de
•Drug: Placebo of France
Other Ids: Phase: Age: Saint Etienne Primary Completion:
Hydroxychloroquine
•CHU de Saint-Etienne, Saint-
Study Documents: •20PH061 Phase 3 18 Years and older •Institut Pasteur November 30, 2020
•Drug: Lopinavir and Étienne, France
ritonavir (Adult, Older
•2020-001188-96
•Drug: Placebo of
•Allocation: Randomized November 30, 2020
LPV/r Tablets Sex:
All First Posted:
Assignment
March 31, 2020
•Masking: Triple
(Participant, Investigator,
Outcomes Assessor)
No Results Posted
•Primary Purpose:
Prevention Last Update Posted:
March 31, 2020
Outcome Measures:
•Occurrence of an
symptomatic or
asymptomatic SARS-
CoV-2 infection among
healthcare workers
(HCWs)
•Evaluation of the
occurrence of adverse
events in each arm,
discontinuation rates of the
investigational drug in each
arm,
adherence of participants
to study drug,
•Evaluation of the incidence
of symptomatic cases of
SARS-CoV-2 infection in
each arm,
of asymptomatic cases of
SARS-CoV-2 infection in
each arm
of severe cases of SARS-
CoV-2 infection in each
arm.
- Page 9 of 73 -
Collaborators Type
12 NCT04330586 A Trial of Ciclesonide in Adults Title Acronym: Not yet •COVID-19 •Drug: Ciclesonide Study Type: Enrollment: •Korea University •Other Study Start:
With Mild COVID-19 recruiting Metered Dose Interventional 141 Guro Hospital April 1, 2020
Other Ids: Inhaler [Alvesco]
Study Documents: KUMC-COVID-19 •Drug: Phase: Age: Primary Completion:

Hydroxychloroquine Phase 2 18 Years to 80 June 30, 2020
Years (Adult,
•Allocation: Randomized September 30, 2020
Sex:
All First Posted:
Assignment
April 1, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
April 1, 2020
•Rate of SARS-CoV-2
eradication at day 14 from
study enrollment
•Rate of SARS-CoV-2
eradication at day 7 from
study enrollment
•Time to SARS-CoV-2
eradication (days)
•Viral load area-under-the-
curve (AUC) reduction
versus control
•Time to clinical
improvement (days)
•Proportion of clinical failure
- Page 10 of 73 -
Collaborators Type
13 NCT04317092 Tocilizumab in COVID-19 Title Acronym: Recruiting •COVID-19 •Drug: Tocilizumab Study Type: Enrollment: •National Cancer •Other Study Start: •Azienda Ospedaliera
Pneumonia (TOCIVID-19) TOCIVID-19 Pneumonia Injection Interventional 330 Institute, Naples March 19, 2020 "SS. Antonio e Biagio e
C. Arrigo" (Dipartimento
Other Ids: Phase: Age: Primary Completion: Internistico SSD
Study Documents: Reumatologia), Alessandria,
•TOCIVID-19 Phase 2 Child, Adult, Older December 19, 2020 Italy
Adult
•2020-001110-38 •Ospedale di Busto Arsizio
Study Design: Study Completion:
Sex: ASST Valle Olona (U.O.C.
•Intervention Model: Single December 19, 2022
Malattie Infettive), Busto
Group Assignment All
Arsizio, Italy
•Masking: None (Open First Posted:
•A.O.U. Policlinico V. Emanuele
(U.O. di Malattie infettive, U.O.
•Primary Purpose: di Anestesia e Rianimazione,
Treatment U.O. di Medicina d'Urgenza),
No Results Posted Catania, Italy
Outcome Measures: •AOE Cannizzaro di Catania
Last Update Posted:
•One-month mortality rate (U.O. di Malattie Infettive, U.O.
March 20, 2020 di Anestesia e Rianimazione,
•Interleukin-6 level
U.O., Catania, Italy
•Lymphocyte count
•Ospedale Annunziata Azienda
•CRP (C-reactive protein) Ospedaliera di Cosenza
level (U.O.C. Malattie Infettive),
Cosenza, Italy
•PaO2 (partial pressure of
oxygen) / FiO2 (fraction •ASST OVEST MILANESE
of inspired oxygen, FiO2) presidi Legnano - Magenta,
ratio (or P/F ratio) Magenta, Italy
•Change of the SOFA •Azienda Ospedaliero-
(Sequential Organ Failure Universitaria di Modena,
Assessment) Modena, Italy
•Number of participants •A.O.U. di Modena
with treatment-related side (Dipartimento Chirurgie
effects as assessed by Generali e Specialità
Common Terminology Chirurgiche - Struttura
Criteria for Adverse Event Complessa di Anestesia e
(CTCAE) version 5.0 Rianimazione I), Modena, Italy
•Radiological response •A.O.U. di Modena
(Dipartimento Chirurgie
•Duration of hospitalization
Generali e Specialità
•Remission of respiratory Chirurgiche - Struttura
symptoms Complessa di Anestesia e
Rianimazione II), Modena, Italy
•A.O.U. di Modena
(Dipartimento Medicine
Specialistiche - Struttura
Complessa Malattie Infettive),
Modena, Italy
•and 17 more
- Page 11 of 73 -
Collaborators Type
14 NCT04275947 The COVID-19 Mobile Health Title Acronym: Recruiting •COVID-19 •Other: nCapp, a Study Type: Enrollment: •Chinese Alliance •Other Study Start: •Renmin Hospital of Wuhan
Study (CMHS) CMHS cell phone-based Observational 450 Against Lung February 14, 2020 University, Wuhan, Hubei,
auto-diagnosis Cancer China
Other Ids: system Phase: Age: Primary Completion:
Study Documents: •Shanghai
CAALC-008-CMHS 18 Years to 90 Respiratory April 30, 2020
Study Design: Years (Adult, Research
•Observational Model: Older Adult) Institution Study Completion:
Cohort May 31, 2020
Sex:
February 19, 2020
Outcome Measures:
Accuracy of nCapp Results First Posted:
COVID-19 risk diagnostic No Results Posted
model
Last Update Posted:
February 19, 2020
- Page 12 of 73 -
Collaborators Type
15 NCT04315298 Evaluation of the Efficacy Title Acronym: Recruiting •COVID-19 •Drug: Sarilumab Study Type: Enrollment: •Regeneron •Industry Study Start: •Regeneron Study Site, Los
and Safety of Sarilumab in Interventional 400 Pharmaceuticals March 16, 2020 Angeles, California, United
•Drug: Placebo
Hospitalized Patients With Other Ids: States
•Sanofi
COVID-19 6R88-COV-2040 Phase: Age: Primary Completion: •Regeneron Study Site, Palo
•Phase 2 18 Years and older March 16, 2021 Alto, California, United States
Study Documents: (Adult, Older •Regeneron Study Site,
•Phase 3
Adult) Study Completion: Sacramento, California, United
Study Design: March 16, 2021 States
Sex:
•Allocation: Randomized •Regeneron Study Site, Santa
All First Posted: Monica, California, United
•Intervention Model: Parallel March 19, 2020 States
Assignment
•Regeneron Study Site, Aurora,
Colorado, United States
Investigator, Outcomes •Regeneron Study Site, Denver,
Assessor) Last Update Posted: Colorado, United States
•Primary Purpose: March 30, 2020 •Regeneron Study Site, New
Treatment Haven, Connecticut, United
States
Outcome Measures: •Regeneron Study Site,
•Time to resolution of Washington, District of
fever for at least 48 hours Columbia, United States
without antipyretics for 48
hours •Regeneron Study Site, Coral
Gables, Florida, United States
•Percentage of patients
reporting each severity •Regeneron Study Site,
rating on a 6-point ordinal Gainesville, Florida, United
scale States
•Time to improvement in •and 47 more

oxygenation for at least 48
hours
•Mean change in the 6-point
ordinal scale
•Clinical status using the 6-
point ordinal scale
•Time to improvement
in one category from
admission using the 6-
point ordinal scale
•Time to resolution of
fever for at least 48 hours
without antipyretics by
clinical severity
•Time to resolution of
fever for at least 48 hours
without antipyretics by
baseline IL-6 levels
•Time to improvement in
oxygenation for at least 48
hours by clinical severity
•Time to improvement in
oxygenation for at least
48 hours by baseline IL-6
levels
•and 30 more
- Page 13 of 73 -
Collaborators Type
16 NCT04330638 Treatment of COVID-19 Patients Title Acronym: Not yet •COVID-19 •Other: Usual Care Study Type: Enrollment: •University •Other Study Start: •AZ Sint-Jan Brugge, Brugge,
With Anti-interleukin Drugs COV-AID recruiting Interventional 342 Hospital, Ghent April 2020 Belgium
•Drug: Anakinra
•Belgium Health •University Hospital Saint-Pierre,
Other Ids: •Drug: Siltuximab Phase: Age: Primary Completion:
Study Documents: Care Knowledge Brussels, Belgium
COV-AID •Drug: Tocilizumab Phase 4 8 Years to 80 Centre September 2020 •Erasmus University Hospital,
Years (Child, Brussels, Belgium
Study Design: Adult, Older Adult) Study Completion:
•University Hospital Saint-Luc,
•Allocation: Randomized December 2020
Sex: Brussels, Belgium
•Intervention Model:
All First Posted: •University Hospital Antwerp,
Factorial Assignment
April 1, 2020 Edegem, Belgium
•Ziekenhuis Oost-Limurg, Genk,
Label)
Results First Posted: Belgium
•Primary Purpose: No Results Posted •University Hospital Ghent,
Treatment
Gent, Belgium
Last Update Posted:
Outcome Measures: •University Hospital Brussels,
April 1, 2020
•Time to Clinical Jette, Belgium
Improvement •University Hospital Liège,
•Time to improvement in Liège, Belgium
oxygenation
•Mean change in
oxygenation
•Number of days with
hypoxia
•Number of days of
supplemental oxygen use
•Time to absence fever for
more than 48h without
antipyretics
•Number of days with fever
•Time to halving of CRP
levels compared to peak
value during trial
•Time to halving of ferritin
levels compared to peak
value during trial
•Incidence of AEs (Adverse
Events)
•and 29 more
- Page 14 of 73 -
Collaborators Type
17 NCT04304313 A Pilot Study of Sildenafil in Title Acronym: Recruiting •COVID-19 •Drug: Sildenafil Study Type: Enrollment: •Tongji Hospital •Other Study Start: •Department and Institute of
COVID-19 citrate tablets Interventional 10 February 9, 2020 Infectious Disease, Wuhan,
Other Ids: Hubei, China
Study Documents: GST-G1 Phase: Age: Primary Completion:

Phase 3 18 Years and older March 1, 2020
(Adult, Older
•Intervention Model: Single November 9, 2020
All First Posted:
•Primary Purpose:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•Rate of disease remission
March 17, 2020
•Rate of entering the critical
stage
•Time of entering the critical
stage
•Rate of no fever
•Rate of respiratory
symptom remission
•Rate of lung imaging
recovery
•Rate of C-reactive protein
(CRP) recovery
•Rate of Biochemical
criterion (CK, ALT, Mb)
recovery
•Rate of undetectable viral
RNA (continuous twice)
•Time for hospitalization
•Rate of adverse event
- Page 15 of 73 -
Collaborators Type
18 NCT04327674 The Use of Focused Lung Title Acronym: Recruiting •COVID-19 Study Type: Enrollment: •University of •Other Study Start: •Lungemedicinsk
Ultrasound in Patients Observational 375 Aarhus March 14, 2020 Forskningsafdeling. Aarhus
Suspected of COVID-19 Other Ids: University Hospital, Aarhus,
COVID-FLUS Phase: Age: Primary Completion: Denmark
Study Documents: 18 Years and older May 15, 2020 •Regionshospitalet Horsens.,
Study Design: (Adult, Older Horsens, Denmark
•Observational Model: Adult) Study Completion:
Cohort May 15, 2020
Sex:
March 31, 2020
Outcome Measures:
•FLUS findings and Results First Posted:
respiratory failure No Results Posted
•FLUS findings and chest x-
ray. Last Update Posted:
March 31, 2020
•FLUS findings and
admission to intensive
care.
•FLUS findings and SAR-
CoV-2 PCR-test result.
- Page 16 of 73 -
Collaborators Type
19 NCT04329923 The PATCH Trial (Prevention Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •Ravi Amaravadi, •Other Study Start: •University of Pennsylvania,
And Treatment of COVID-19 PATCH recruiting Hydroxychloroquine Interventional 400 MD April 6, 2020 Philadelphia, Pennsylvania,
With Hydroxychloroquine) Sulfate 400 mg United States
•University of
Other Ids: twice a day Phase: Age: Primary Completion:
Pennsylvania
Study Documents: 842838 •Drug: Phase 2 18 Years and older April 1, 2021
Hydroxychloroquine (Adult, Older
Sulfate 600 mg Study Design: Adult) Study Completion:
twice a day
•Drug: Sex:
Hydroxychloroquine All First Posted:
Assignment
Sulfate 600 mg
April 1, 2020
once a day •Masking: Triple
(Participant, Care Provider,
•Drug: Placebo oral Results First Posted:
Investigator)
tablet No Results Posted
•Primary Purpose:
April 1, 2020
Outcome Measures:
•Median release from
quarantine time
•Rate of hospital discharge
•Rate of infection
•Rate of housemate
infection
•Rate of hospitalization
•Cohort 1 adverse event
rate
•Time to condition
appropriate for discharge
•Rate of ICU admission
•Time to PCR negativity
•Cohort 2 adverse events
•Scheduled shifts missed
•Cohort 3 adverse events
- Page 17 of 73 -
Collaborators Type
20 NCT04330690 Treatments for COVID-19: Title Acronym: Active, not •COVID-19 •Drug: Lopinavir/ Study Type: Enrollment: •Sunnybrook •Other Study Start: •Sunnybrook Health Sciences
Canadian Arm of the CATCO recruiting ritonavir Interventional 440 Health Sciences March 18, 2020 Centre, Toronto, Ontario,
•Industry
SOLIDARITY Trial Centre Canada
Other Ids: Phase: Age: •AbbVie Primary Completion:
Study Documents: 2114 Phase 2 6 Months and older March 18, 2022
(Child, Adult,
•Allocation: Randomized May 18, 2022
Sex:
All First Posted:
Assignment
April 1, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
April 1, 2020
•Efficacy of Intervention
•Time to improvement
of one catergory from
admission
•Subject clinical status
•Change in Subject clinical
status
•Oxygen free days
•Incidence of oxygen use
•Duration of oxygen use
•Incidence of new
•Duration of mechanical
ventilation
•Mortality
•Cumulative Incidence of
Grade 3 and 4 Adverse
Events (AEs) and Serious
Adverse Events (SAEs)
- Page 18 of 73 -
Collaborators Type
21 NCT04318418 ACE Inhibitors, Angiotensin II Title Acronym: Not yet •COVID-19 Study Type: Enrollment: •Neuromed •Other Study Start: •IRCCS Neuromed, Department
Type-I Receptor Blockers and CODIV-ACE recruiting Observational 5000 IRCCS March 23, 2020 of Epidemiology and
Severity of COVID-19 Prevention, Pozzilli, Italy
Other Ids: Phase: Age: Primary Completion:
Study Documents: DEP_012020 Child, Adult, Older April 10, 2020
Study Design: Adult
•Observational Model: Study Completion:
Case-Control Sex: April 30, 2020
•Time Perspective: All
Retrospective First Posted:
March 24, 2020
Outcome Measures:
•Severe COVID-19 Results First Posted:
•Death No Results Posted
Last Update Posted:

March 24, 2020
22 NCT04285801 Critically Ill Patients With Title Acronym: Completed •COVID-19 Study Type: Enrollment: •Chinese •Other Study Start: •Pamela Youde Nethersole
COVID-19 in Hong Kong: a Observational 8 University of February 14, 2020 Eastern Hospital, Hong Kong,
Multicentre Observational Other Ids: Hong Kong Hong Kong
Cohort Study 2020.059 Phase: Age: Primary Completion: •Prince of Wales Hospital, Hong
18 Years and older February 25, 2020 Kong, Hong Kong
Study Documents: Study Design: (Adult, Older •Princess Margaret Hospital,
•Observational Model: Adult) Study Completion: Hong Kong, Hong Kong
Case-Only February 25, 2020
Sex:
Retrospective All First Posted:
February 26, 2020
Outcome Measures:
•28 day mortality Results First Posted:
•vasopressor days No Results Posted
•days on mechanical Last Update Posted:

ventilation
March 10, 2020
•sequential organ function
assessment score
•ECMO use
•percentage nitric oxide use
•percentage free from
oxygen supplement
- Page 19 of 73 -
Collaborators Type
23 NCT04304053 Treatment of COVID-19 Cases Title Acronym: Recruiting •COVID-19 •Drug: Antiviral Study Type: Enrollment: •Fundacio Lluita •Other Study Start: •CAP II Sant Fèlix, Sabadell,
and Chemoprophylaxis of HCQ4COV19 treatment and Interventional 3040 Contra la SIDA March 18, 2020 Barcelona, Spain
Contacts as Prevention prophylaxis
•Germans Trias i •Gerència Territorial Catalunya
Other Ids: •Other: Standard Phase: Age: Pujol Hospital Primary Completion: Central, Sant Fruitós De Bages,
Study Documents: •HCQ4COV19 Public Health Phase 3 18 Years and older June 15, 2020 Barcelona, Spain
•Department
measures (Adult, Older
•2020-001031-27 of Health, •Centre de Salut Isabel Roig-
Study Design: Adult) Generalitat de Study Completion: Casernes de Sant Andreu,
•Allocation: Randomized Catalunya June 15, 2020 Barcelona, Spain
Sex:
•Intervention Model: Parallel •FUNDACIÓN
All First Posted:
Assignment FLS DE LUCHA
CONTRA EL March 11, 2020
SIDA, LAS
Label)
ENFERMEDADES Results First Posted:
•Primary Purpose: INFECCIOSAS No Results Posted
Prevention Y LA
PROMOCIÓN
Last Update Posted:
Outcome Measures: DE LA SALUD Y
LA CIENCIA March 24, 2020
•Effectiveness of
chemoprophylaxis •Laboratorios
assessed by incidence Gebro Pharma
of secondary COVID-19 SA
cases
•Laboratorios
•The virological clearance Rubió
rate of throat swabs,
•Institut Catala de
sputum, or lower
Salut
respiratory tract secretions
at days 3
•The mortality rate of
subjects at weeks 2
•Proportion of participants
that drop out of study
•Proportion of participants
that show non-compliance
with study drug
24 NCT04319315 Social Media Effect on Title Acronym: Recruiting •COVID-19 •Other: survey Study Type: Enrollment: •Assiut University •Other Study Start: •Assiut University Hospitals,
Knowledge Dissemination Observational 400 March 11, 2020 Assiut, Egypt
During COVID-19 Virus Other Ids:
Outbreak AssiutU-3-2020 Phase: Age: Primary Completion:
25 Years to 65 March 16, 2020
Other March 16, 2020
Sex:
March 24, 2020
Outcome Measures:
Number of physicians Results First Posted:
affected by social media No Results Posted
measured by online survey
designed to measure the Last Update Posted:
influence of social media on
March 24, 2020
medical practice
- Page 20 of 73 -
Collaborators Type
25 NCT04321993 Treatment of Moderate to Title Acronym: Not yet •COVID-19 •Drug: Lopinavir/ Study Type: Enrollment: •Lisa Barrett •Other Study Start:
Severe Coronavirus Disease recruiting ritonavir Interventional 1000 March 2020
•Nova Scotia
(COVID-19) in Hospitalized Other Ids: •Drug: Health Authority
Patients SAIL-004 Phase: Age: Primary Completion:
Hydroxychloroquine
•Dalhousie
sulfate Phase 2 18 Years and older February 2021
University
Study Documents: •Drug: Baricitinib (Adult, Older
(janus kinase Study Design: Adult) Study Completion:
inhibitor) •Allocation: Non- July 2021
Randomized Sex:
•Drug: Sarilumab
All First Posted:
(anti-IL-6 receptor) •Intervention Model: Parallel
Assignment March 26, 2020
Label)
No Results Posted
•Primary Purpose:
March 26, 2020
Outcome Measures:
•Clinical status of subject at
day 15 (on a 7 point ordinal
scale).
•Status on an ordinal scale
assessed daily while
hospitalized and on days
15 and 29 and 180.
•Length of time to clinical
improvement
•Number of participants with
normal pulmonary function
and normal O2 saturation
on days 11, 15 and 29
•Number of participants
that developed Acute
Respiratory Distress
Syndrome (ARDS) after
treatment
•Length of time to clinical
progression
•Cause of death (if
applicable)
•Sequential Organ Failure
Assessment (SOFA) score,
daily while hospitalized and
on days 15 and 29. (Initial,
highest, deltas and mean)
•Length of time to
normalization of fever
•Length of time to
normalization of oxygen
saturation
•and 4 more
- Page 21 of 73 -
Collaborators Type
26 NCT04329611 Hydroxychloroquine to Prevent Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •Dr. Michael Hill •Other Study Start: •University of Calgary/Foothills
Covid19 Pneumonia (ALBERTA recruiting Hydroxychloroquine Interventional 1660 April 8, 2020 Medical Centre, Calgary,
•University of
HOPE-Covid19) Other Ids: Alberta, Canada
Calgary
ABCOV-01 Phase: Age: Primary Completion:
Study Documents: Phase 3 18 Years and older July 31, 2020
(Adult, Older
•Allocation: Randomized August 31, 2020
Sex:
•Intervention Model: Single
All First Posted:
Group Assignment
April 1, 2020
•Masking: Triple
Investigator)
No Results Posted
•Primary Purpose:
April 1, 2020
Outcome Measures:
•Composite of
hospitalization, invasive
mechanical ventilation or
death within 30 days
•composite of invasive
mechanical ventilation or
death within 30 days
•invasive mechanical
ventilation
•hospitalization within 30
days
•mortality
27 NCT04313023 The Use PUL-042 Inhalation Title Acronym: Not yet •COVID-19 •Drug: PUL-042 Study Type: Enrollment: •Pulmotect, Inc. •Industry Study Start:
Solution to Prevent COVID-19 in recruiting Inhalation Solution Interventional 200 April 2020
Adults Exposed to SARS-CoV-2 Other Ids: •Drug: Placebo
PUL-042-501 Phase: Age: Primary Completion:
Study Documents: Phase 2 18 Years and older September 2020
(Adult, Older
•Allocation: Randomized October 2020
Sex:
All First Posted:
Assignment
March 18, 2020
•Masking: Quadruple
Assessor) No Results Posted
•Primary Purpose: Last Update Posted:

Prevention
March 24, 2020
Outcome Measures:
Prevention of COVID-19
- Page 22 of 73 -
Collaborators Type
28 NCT04307693 Comparison of Lopinavir/ Title Acronym: Recruiting •COVID-19 •Drug: Lopinavir/ Study Type: Enrollment: •Asan Medical •Other Study Start: •Asan Medical Center,
Ritonavir or Hydroxychloroquine ritonavir Interventional 150 Center March 11, 2020 University of Ulsan College
in Patients With Mild Other Ids: of Medicine, Seoul, Korea,
•Drug:
Coronavirus Disease S2020-0472-0001 Phase: Age: Primary Completion: Republic of
Hydroxychloroquine
(COVID-19)
sulfate Phase 2 16 Years to 99 May 2020
Years (Child,
Study Documents: Study Design: Adult, Older Adult) Study Completion:
•Allocation: Randomized May 2020
Sex:
All First Posted:
Assignment
March 13, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 13, 2020
•Viral load
•Viral load change
•Time to clinical
improvement (TTCI)
•Percentage of progression
to supplemental oxygen
requirement by day 7
•Time to NEWS2 (National
Early Warning Score 2) of
3 or more maintained for
24 hours by day 7
•Time to clinical failure,
defined as the time
to death, mechanical
ventilation, or ICU
admission
•Rate of switch to
Lopinavir/ritonavir or
hydroxychloroquine by day
7
•adverse effects
•Concentration of
Lopinavir/ritonavir and
hydroxychloroquine
- Page 23 of 73 -
Collaborators Type
29 NCT04323631 Hydroxychloroquine for the Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •Rambam Health •Other Study Start:
Treatment of Patients With recruiting Hydroxychloroquine Interventional 1116 Care Campus March 2020
Mild to Moderate COVID-19 to Other Ids: •Other: The •Rabin Medical
Prevent Progression to Severe 0154-20-RMB Phase: Age: Primary Completion:
control group Center
Infection or Death
will not receive Early Phase 1 18 Years and older December 2020
hydroxychloroquine (Adult, Older
Study Documents: Study Design: Adult) Study Completion:
Sex:
All First Posted:
Sequential Assignment
March 26, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 26, 2020
Number patients developing
severe infection or death
30 NCT04292899 Study to Evaluate the Safety and Title Acronym: Recruiting •COVID-19 •Drug: Remdesivir Study Type: Enrollment: •Gilead Sciences •Industry Study Start: •Kaiser Permanente Los
Antiviral Activity of Remdesivir Interventional 400 March 6, 2020 Angeles Medical Center, Los
•Drug: Standard of
(GS-5734™) in Participants With Other Ids: Angeles, California, United
Care
Severe Coronavirus Disease •GS-US-540-5773 Phase: Age: Primary Completion: States
(COVID-19)
•2020-000841-15 Phase 3 18 Years and older May 2020 •Hoag Memorial Hospital
(Adult, Older Presbyterian, Newport Beach,
Study Documents: Study Design: Adult) Study Completion: California, United States
•Allocation: Randomized May 2020 •Providence St. Johns Medical
Sex: Center, Santa Monica,
All First Posted: California, United States
Assignment
March 3, 2020 •Stanford Hospital, Stanford,
California, United States
Label)
•University of Chicago, Chicago,
•Primary Purpose: No Results Posted Illinois, United States
Treatment
Last Update Posted: •Brigham & Women's Hospital
Outcome Measures: and Harvard Medical School,
March 31, 2020 Boston, Massachusetts, United
•Proportion of Participants
States
With Normalization
of Fever and Oxygen •Beth Israel Deaconess
Saturation Through Day 14 Medical Center, Boston,
Massachusetts, United States
With Treatment Emergent •Hackensack University Medical
Adverse Events Leading to Center, Hackensack, New
Study Drug Discontinuation Jersey, United States
•Jamaica Hospital Medical
Center, Jamaica, New York,
United States
•Danbury Hospital,
Lagrangeville, New York,
United States
•and 34 more
- Page 24 of 73 -
Collaborators Type
31 NCT04312997 The Use of PUL-042 Inhalation Title Acronym: Not yet •COVID-19 •Drug: PUL-042 Study Type: Enrollment: •Pulmotect, Inc. •Industry Study Start: •Houston Methodist Hospital,
Solution to Reduce the Severity recruiting Inhalation Solution Interventional 100 April 2020 Houston, Texas, United States
of COVID-19 in Adults Positive Other Ids: •Drug: Placebo
for SARS-CoV-2 Infection PUL-042-502 Phase: Age: Primary Completion:
Phase 2 18 Years and older September 2020
•Allocation: Randomized October 2020
Sex:
All First Posted:
Assignment
March 18, 2020

Treatment
March 24, 2020
Outcome Measures:
•Severity of COVID-19
•All cause mortality
32 NCT04329572 Efficacy and Safety of Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •Azidus Brasil •Industry Study Start:
Hydroxychloroquine and recruiting Hydroxychloroquine Interventional 400 April 3, 2020
•PREVENT •Other
Azithromycin for the Treatment Other Ids: Sulfate and
SENIOR
of Hospitalized Patients With HIAPRE0320OR azithromycin Phase: Age: Primary Completion:
PRIVATE
Moderate to Severe COVID-19
Early Phase 1 18 Years and older OPERADORA May 31, 2020
(Adult, Older DE SAÚDE
Study Documents: Study Design: Adult) LTDA Study Completion:
•Intervention Model: Single June 30, 2020
All First Posted:
Label) April 1, 2020
•Primary Purpose:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•Evolution of acute
respiratory syndrome, April 1, 2020
oxygen saturation
hemodynamic stability
•Viral load
•Change in Clinical
Condition
•Evolution of Acute
Respiratory Syndrome
•Hospital discharge
•Rate of mortality within 28-
days
- Page 25 of 73 -
Collaborators Type
33 NCT04292730 Study to Evaluate the Safety and Title Acronym: Recruiting •COVID-19 •Drug: Remdesivir Study Type: Enrollment: •Gilead Sciences •Industry Study Start: •Kaiser Permanente Los
Antiviral Activity of Remdesivir Interventional 600 March 15, 2020 Angeles Medical Center, Los
•Drug: Standard of
(GS-5734™) in Participants Other Ids: Angeles, California, United
Care
With Moderate Coronavirus •GS-US-540-5774 Phase: Age: Primary Completion: States
Disease (COVID-19) Compared
•2020-000842-32 Phase 3 18 Years and older May 2020 •Hoag Memorial Hospital
to Standard of Care Treatment
(Adult, Older Presbyterian, Newport Beach,
Study Design: Adult) Study Completion: California, United States
Study Documents: •Stanford Hospital, Stanford,
Sex: California, United States
All First Posted:
Assignment •University of Chicago, Chicago,
March 3, 2020 Illinois, United States
Label) •Brigham & Women's Hospital
and Harvard Medical School,
•Primary Purpose: No Results Posted Boston, Massachusetts, United
Treatment
States
Last Update Posted:
Outcome Measures: •Center for Virology and
March 31, 2020 Vaccine Research, Beth Israel
Deaconess Medical Center,
Discharged by Day 14
Boston, Massachusetts, United
•Proportion of Participants States
With Treatment Emergent
•Jamaica Hospital Medical
Adverse Events Leading to
Center, Jamaica, New York,
Study Drug Discontinuation
United States
•Danbury Hospital,
Lagrangeville, New York,
United States
•Providence Portland Medical
Center, Portland, Oregon,
United States
•Providence St. Vincent Medical
Center, Portland, Oregon,
United States
•and 31 more
- Page 26 of 73 -
Collaborators Type
34 NCT04315987 NestCell® Mesenchymal Stem Title Acronym: Not yet •COVID-19 •Biological: Study Type: Enrollment: •Azidus Brasil •Industry Study Start: •Prevent Senior Private
Cell to Treat Patients With HOPE recruiting Pneumonia NestCell® Interventional 66 April 2020 Operadora de Saúde LTDA.,
•Cellavita •Other
Severe COVID-19 Pneumonia São Paulo, Brazil
Pesquisa
Other Ids: Phase: Age: Científica Ltda Primary Completion:
Study Documents: HOPE Phase 1 18 Years and older •Hospital Vera May 2020
(Adult, Older Cruz
•Allocation: Non- June 2020
Randomized Sex:
All First Posted:
Group Assignment March 20, 2020
Label)
No Results Posted
•Primary Purpose:
March 31, 2020
Outcome Measures:
•Disappear time of ground-
glass shadow in the lungs
days
•Change of Clinical
symptoms including
duration of fever and
respiratory
•Time of nucleic acid
turning negative
•CD4+ and CD8+ T cell
count
•Changes of blood oxygen
•Side effects in the
treatment group
35 NCT04305106 Bevacizumab in Severe or Title Acronym: Recruiting •COVID-19 •Drug: Bevacizumab Study Type: Enrollment: •Qilu Hospital •Other Study Start: •Qilu Hospital of Shandong
Critically Severe Patients With BEST-RCT Pneumonia Interventional 140 of Shandong March 17, 2020 University, Jinan, Shandong,
COVID-19 Pneumonia-RCT University China
Other Ids: Phase: Age: •Renmin Hospital Primary Completion:
Study Documents: QLEmer Not Applicable 18 Years to 80 of Wuhan June 30, 2020
Years (Adult, University
Study Design: Older Adult) •Ialy Moriggia Study Completion:
•Allocation: Randomized Pelascini July 31, 2020
Sex: Gravedona
All Hospital S.p.A First Posted:
Assignment
•Wuhan March 12, 2020
•Masking: Triple
University
Outcomes Assessor) •Jiangbei Union
Hospital of No Results Posted
•Primary Purpose:
Huazhong
University of
science and March 26, 2020
Outcome Measures: technology
The time from
•Shandong
randomization to clinical
Provincial Chest
improvement
Hospital
- Page 27 of 73 -
Collaborators Type
36 NCT04320615 A Study to Evaluate the Safety Title Acronym: Not yet •COVID-19 •Drug: Tocilizumab Study Type: Enrollment: •Hoffmann-La •Industry Study Start:
and Efficacy of Tocilizumab in COVACTA recruiting Pneumonia (TCZ) Interventional 330 Roche April 3, 2020
Patients With Severe COVID-19
•Drug: Placebo
Pneumonia Other Ids: Phase: Age: Primary Completion:
•WA42380 Phase 3 18 Years and older August 31, 2021
•2020-001154-22
Sex:
All First Posted:
Assignment
March 25, 2020
•Masking: Double
(Participant, Investigator)
Treatment
Last Update Posted:
Outcome Measures:
March 30, 2020
•Clinical Status Assessed
Using a 7-Category Ordinal
Scale
•Time to Clinical
Improvement (TTCI),
Defined as a National Early
Warning Score 2 (NEWS2)
of </= 2 Maintained for 24
Hours
•Time to Improvement of
at Least 2 Categories
Relative to Baseline on a
7-Category Ordinal Scale
of Clinical Status
•Incidence of Mechanical
Ventilation
•Ventilator-Free Days to
Day 28
•Organ Failure-Free Days
to Day 28
•Incidence of Intensive Care
Unit (ICU) Stay
•Duration of ICU Stay
•Time to Clinical Failure
•Mortality Rate
•and 11 more
- Page 28 of 73 -
Collaborators Type
37 NCT04313322 Treatment of COVID-19 Title Acronym: Recruiting •Use of Stem Cells •Biological: WJ- Study Type: Enrollment: •Stem Cells •Other Study Start: •Stem Cells Arabia, Amman,
Patients Using Wharton's Jelly- for COVID-19 MSCs Interventional 5 Arabia March 16, 2020 Jordan
Mesenchymal Stem Cells Other Ids: Treatment
COVID-19 Phase: Age: Primary Completion:
Study Documents: Phase 1 18 Years and older June 30, 2020
(Adult, Older
•Intervention Model: Single September 30, 2020
All First Posted:
•Primary Purpose:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•Clinical outcome
March 18, 2020
•CT Scan
•RT-PCR results
38 NCT04308317 Tetrandrine Tablets Used in the Title Acronym: Enrolling by •Corona Virus •Drug: Tetrandrine Study Type: Enrollment: •Henan Provincial •Other Study Start: •Tetrandrine Tablets, Jinhua,
Treatment of COVID-19 TT-NPC invitation Disease Interventional 60 People's March 5, 2020 Zhejiang, China
2019,COVID-19 Hospital
Study Documents: Other Ids: Phase: Age: Primary Completion:

TT-NPC Phase 4 18 Years to 75 March 1, 2021
Years (Adult,
Sex:
All First Posted:
Assignment
March 16, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 16, 2020
•Survival rate
•body temperature
- Page 29 of 73 -
Collaborators Type
39 NCT04273529 The Efficacy and Safety of Title Acronym: Not yet •COVID-19 •Drug: thalidomide Study Type: Enrollment: •First Affiliated •Other Study Start:
Thalidomide in the Adjuvant recruiting Thalidomide Interventional 100 Hospital of February 20, 2020
•Drug: placebo
Treatment of Moderate New Other Ids: Wenzhou
Coronavirus (COVID-19) 20200214- Phase: Age: Medical Primary Completion:
Pneumonia COVID-19-M-T University
Phase 2 18 Years and older May 30, 2020
(Adult, Older •Second Affiliated
Study Documents: Study Design: Adult) Hospital of Study Completion:
Wenzhou
Sex: Medical
•Intervention Model: Parallel University
All First Posted:
Assignment
•Wenzhou
February 18, 2020
•Masking: Quadruple Central Hospital

Treatment
February 21, 2020
Outcome Measures:
•Time to Clinical
recoveryTime to Clinical
Recovery (TTCR)
•Frequency of respiratory
progression
•Time to defervescence
- Page 30 of 73 -
Collaborators Type
40 NCT04273581 The Efficacy and Safety of Title Acronym: Not yet •COVID-19 •Drug: placebo Study Type: Enrollment: •First Affiliated •Other Study Start:
Thalidomide Combined With recruiting Thalidomide Interventional 40 Hospital of February 18, 2020
•Drug: Thalidomide
Low-dose Hormones in the Other Ids: Wenzhou
Treatment of Severe COVID-19 20200214- Phase: Age: Medical Primary Completion:
COVID-19-S-T University
Phase 2 18 Years and older April 30, 2020
Study Documents: (Adult, Older •Second Affiliated
Study Design: Adult) Hospital of Study Completion:
Wenzhou
Sex: Medical
•Intervention Model: Parallel University
All First Posted:
Assignment
•Wenzhou
February 18, 2020
•Masking: Quadruple Central Hospital

Treatment
February 21, 2020
Outcome Measures:
•Time to Clinical
Improvement (TTCI)
•Clinical status
•Time to Hospital Discharge
OR NEWS2 (National
Early Warning Score 2)
of # 2 maintained for 24
hours
extracorporeal membrane
oxygenation
(days)
•Time to 2019-nCoV RT-
PCR negativity in upper
and lower respiratory tract
specimens
•Change (reduction) in
2019-nCoV viral load
in upper and lower
respiratory tract specimens
as assessed by area under
viral load curve.
•Frequency of serious
adverse drug events
•Serum TNF-#, IL-1#, IL-2,
IL-6, IL-7, IL-10, GSCF,
IP10#MCP1, MIP1# and
other cytokine expression
levels before and after
treatment
- Page 31 of 73 -
Collaborators Type
41 NCT04312464 Myocardial Damage in Title Acronym: Enrolling by •COVID-19 •Other: non Study Type: Enrollment: •Wuhan Union •Other Study Start: •Department of Cardiology,
COVID-19 invitation Observational 500 Hospital, China January 1, 2020 Union Hospital, Tongji Medical
•Cardiovascular
Other Ids: College, Huazhong University
Diseases
MD-COVID-19 Phase: Age: Primary Completion: of Science and Technology,
Study Documents: Wuhan, Hubei, China
18 Years and older March 15, 2020
Study Design: (Adult, Older
Case-Control March 18, 2020
Sex:
March 18, 2020
Outcome Measures:
•The myocardial injury Results First Posted:
incidence No Results Posted
•The risk factors analysis
for the death Last Update Posted:
March 18, 2020
•Clinical characteristics
•Clinical course
•Cardiovascular comorbidity
•Analysis of causes of
death
- Page 32 of 73 -
Collaborators Type
42 NCT04329650 Efficacy and Safety of Title Acronym: Not yet •COVID-19 •Drug: Siltuximab Study Type: Enrollment: •Judit Pich •Other Study Start: •Hospital Clínic de Barcelona,
Siltuximab vs. Corticosteroids recruiting Interventional 100 Martínez April 1, 2020 Barcelona, Spain
•Drug:
in Hospitalized Patients With Other Ids: Methylprednisolone •Fundacion Clinic
COVID19 Pneumonia SILCOR- Phase: Age: Primary Completion:
per a la Recerca
COVID-19 Phase 2 18 Years and older Biomédica May 20, 2020
Sex:
All First Posted:
Assignment
April 1, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
April 1, 2020
•Proportion of patients
requiring ICU admission at
any time within the study
period.
•Days of stay in the ICU
during the study period.
•Days until resolution of
fever defined as body
temperature (axillary #
36.6 ° C, oral # 37.2 ° C, or
rectal or tympanic # 37.8
° C) for at least 48 hours,
without administration of
antipyretics or until hospital
discharge.
•Proportion of patients with
a worsening requirement of
supplemental oxygen at 29
days. days.
•Days with hypoxemia
(SpO2 <93% in ambient
air or requiring oxygen
supplemental or
support) at 29 days.
•Proportion of patients
using mechanical
ventilation at 29 days.
•Days with use of
mechanical ventilation at
29 days.
•Days until the start of use
of mechanical ventilation,
non-invasive ventilation
or use of high flow nasal
cannula (if the patient have
not previously required
these interventions at the
inclusion of the study) at
29 days.
•Days of hospitalization
among survivors at 29
- Page 33 days.
of 73 -
•Mortality rate from any

Collaborators Type
43 NCT04280588 Fingolimod in COVID-19 Title Acronym: Recruiting •Coronavirus •Drug: Fingolimod Study Type: Enrollment: •First Affiliated •Other Study Start: •Wan-Jin Chen, Fuzhou, China
Disease 0.5 mg Interventional 30 Hospital of February 22, 2020
Other Ids: (COVID-19) Fujian Medical
Study Documents: University
MRCTA, ECFAH of Phase: Age: Primary Completion:
FMU [2020]027 Phase 2 18 Years to 80 July 1, 2020
Years (Adult,
•Allocation: Non- July 1, 2020
Randomized Sex:
All First Posted:
Assignment February 21, 2020
Label)
No Results Posted
•Primary Purpose:
February 21, 2020
Outcome Measures:
The change of pneumonia
severity on X-ray images
44 NCT04325061 Efficacy of Dexamethasone Title Acronym: Not yet •Acute Respiratory •Drug: Study Type: Enrollment: •Dr. Negrin •Other Study Start: •Department of Anesthesia,
Treatment for Patients With DEXA-COVID19 recruiting Distress Syndrome Dexamethasone Interventional 200 University April 1, 2020 Hospital Universitario de
ARDS Caused by COVID-19 Caused by Hospital Cruces, Barakaldo, Vizcaya,
Other Ids: COVID-19 Phase: Age: Primary Completion: Spain
•Li Ka Shing
Study Documents: 2020-001278-31 Phase 4 18 Years and older Knowledge October 30, 2020 •Intensive Care Unit, Hospital
(Adult, Older Institute Universitario de Cruces,
Study Design: Adult) Study Completion: Barakaldo, Vizcaya, Spain
•Consorcio
•Allocation: Randomized Centro de October 30, 2020 •Department of Anesthesia,
Sex: Investigación Hospital Clinic, Barcelona,
All Biomédica en First Posted: Spain
Assignment
Red, M.P.
March 27, 2020 •Intensive Care Unit, Hospital
General de Ciudad Real,
Label)
Results First Posted: Ciudad Real, Spain
•Primary Purpose: No Results Posted •Hospital Universitario Dr.
Treatment
Negrin, Las Palmas de Gran
Last Update Posted: Canaria, Spain
Outcome Measures:
April 1, 2020 •Department of Anesthesia,
•60-day mortality
Hospital Universitario La
•Ventilator-free days Princesa, Madrid, Spain
•Intensive Care Unit, Hospital
Universitario La Princesa,
Madrid, Spain
Universitario Fundación
Jiménez Díaz, Madrid, Spain
•Department of Anesthesia,
Hospital Universitario La Paz,
Madrid, Spain
Universitario La Paz, Madrid,
Spain
•and 7 more
- Page 34 of 73 -
Collaborators Type
45 NCT04315896 Hydroxychloroquine Treatment Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •National Institute •Other Study Start:
for Severe COVID-19 Pulmonary HYDRA recruiting Hydroxychloroquine Interventional 500 of Respiratory March 23, 2020
•Severe Acute •Industry
Infection (HYDRA Trial) Diseases,
Respiratory •Drug: Placebo oral
Other Ids: Phase: Age: Mexico Primary Completion:
Syndrome tablet
Study Documents: HidroxycloroquinaCOVID19 Phase 3 18 Years to 80 •Sanofi October 31, 2020
Years (Adult,
•Allocation: Randomized March 22, 2021
Sex:
All First Posted:
Assignment
March 20, 2020

Treatment
March 20, 2020
Outcome Measures:
•All-cause hospital mortality
•Need of mechanical
ventilation
•Ventilator free days
•Grade 3-4 adverse
reaction
- Page 35 of 73 -
Collaborators Type
46 NCT04329559 COVID-19 in Patients With Title Acronym: Recruiting •COVID-19 Study Type: Enrollment: •Hepatopancreatobiliary
•Other Study Start: •Dalian Sixth People's Hospital,
Pre-existing Cirrhosis (COVID- Observational 50 Surgery Institute March 30, 2020 Dalian, China
•Liver Cirrhosis
Cirrhosis-CHESS2002): A Other Ids: of Gansu
•Minda Hospital Affiliated
Multicentre Observational Study CHESS2002 Phase: Age: Province Primary Completion: to Hubei University for
18 Years and older •Renmin Hospital June 29, 2020 Nationalities, Enshi, China
Study Documents: Study Design: (Adult, Older of Wuhan
•The Central Hospital of Enshi
•Observational Model: Adult) University Study Completion: Tujia And Miao Autonomous
Cohort •LanZhou June 29, 2021 Prefecture, Enshi, China
Sex: University
•Time Perspective: Cross- •The First Hospital of Lanzhou
Sectional All First Posted:
•Minda Hospital University, Lanzhou, China
Affiliated to April 1, 2020
Outcome Measures: •The Central Hospital of Lishui
Hubei University
City, Lishui, China
•All-cause mortality of for Nationalities Results First Posted:
COVID-19 patients with No Results Posted •Guangxi Zhuang Autonomous
•Wuhan Union
liver cirrhosis Region, Nanning, China
Hospital, China
•Liver-related mortality of Last Update Posted: •The Sixth Peoples Hospital of
•The Central
COVID-19 patients with April 1, 2020 Shenyang, Shenyang, China
Hospital of Enshi
liver cirrhosis Tujia And Miao •Shenzhen Third People's
•Risk factors associated Autonomous Hospital, Shenzhen, China
with specific outcomes of Prefecture
•Suizhou Hospital, Hubei
COVID-19 patients with •Tianjin Second University of Medicine,
liver cirrhosis People's Suizhou, China
•Baseline characteristics Hospital
•Tianjin Second People's
of COVID-19 patients with •Sixth People’s Hospital, Tianjin, China
liver cirrhosis Hospital of
Shenyang •and 5 more
•Guangxi Zhuang
Autonomous
Region
•Shenzhen
Third People's
Hospital
•and 6 more
47 NCT04318301 Hypertension in Patients Title Acronym: Active, not •COVID-19 Study Type: Enrollment: •Zhenhua Zen •Other Study Start: •Hankou Hospital, Hankou,
Hospitalized With COVID-19 HT-COVID19 recruiting Observational 275 March 21, 2020 Hubei, China
•Hypertension •Nanfang
Hospital of
Study Documents: Other Ids: Phase: Age: Southern Primary Completion:
Zhenhuazen2018 18 Years to 100 Medical March 28, 2020
Study Design: Years (Adult, University
Sex:
March 23, 2020
Outcome Measures:
•Rate of Death Results First Posted:
•the severity of pneumonia No Results Posted
Last Update Posted:

March 24, 2020
- Page 36 of 73 -
Collaborators Type
48 NCT04326920 Sargramostim in Patients With Title Acronym: Recruiting •COVID-19 Infection •Drug: Study Type: Enrollment: •University •Other Study Start: •AZ Sint Jan Brugge, Brugge,
Acute Hypoxic Respiratory SARPAC With Acute Hypoxic Sargramostim Interventional 80 Hospital, Ghent March 24, 2020 Belgium
Failure Due to COVID-19 Respiratory Failure
•Other: Control •Flanders •San Matteo Hospital, Pavia,
(SARPAC) Other Ids: Phase: Age: Primary Completion:
Institute of Italy
SARPAC Phase 4 18 Years to 80 Biotechnology October 31, 2020
Sex:
All First Posted:
Assignment
March 30, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 30, 2020
•Improvement in
oxygenation at a dose of
250 mcg daily during 5
days improves oxygenation
in COVID-19 patients with
acute hypoxic respiratory
failure
•Incidence of AE (Adverse
Event)
•Incidence of SAEs
(Serious Adverse Event)
•Clinical Status using 6-
point ordinal scale
•Clinical Status using
Clincal sign score
•Clinical Status using SOFA
score (Sequential Organ
Failure Assessment score),
•Clinical Status using
NEWS2 score (National
Early Warning Score)
•incidence of severe or
life-threatening bacterial,
invasive fungal or
opportunistic infection
•number of patients
requiring initiation of
•Number of deaths due to
any cause at 4 weeks
•and 5 more
- Page 37 of 73 -
Collaborators Type
49 NCT04330521 Impact of the Coronavirus Title Acronym: Not yet •Cancer Study Type: Enrollment: •Stanford •Other Study Start:
(COVID-19) on Patients With recruiting Observational 50 University April 2020
•COVID-19
Cancer Other Ids:
55596 Phase: Age: Primary Completion:
Study Documents: 18 Years to 99 May 2022
Study Design: Years (Adult,
Cohort May 2022
Sex:
April 1, 2020
Outcome Measures:
Number of participants Results First Posted:
who fill out the survey and No Results Posted
participate in the semi-
structured interviews. Last Update Posted:
April 1, 2020
50 NCT04328493 The Vietnam Chloroquine Title Acronym: Not yet •SARS-CoV-2 •Drug: Chloroquine Study Type: Enrollment: •Oxford •Other Study Start: •National Hospital for Tropical
Treatment on COVID-19 VICO recruiting Infection phosphate Interventional 250 University April 1, 2020 Diseases, Hanoi, Vietnam
Clinical
•COVID-19 •Can Gio COVID Hospital, Ho
Other Ids: Phase: Age: Research Unit, Primary Completion:
Study Documents: Chi Minh City, Vietnam
Vietnam
COVID Phase 2 18 Years and older April 1, 2021 •Cho Ray Hospital, Ho Chi Minh
(Adult, Older •Ministry of
City, Vietnam
Study Design: Adult) Health, Vietnam Study Completion:
•Cu Chi COVID Hospital, Ho Chi
•Allocation: Randomized •Hospital April 1, 2022
Sex: Minh City, Vietnam
for Tropical
All Diseases, Ho First Posted: •Hospital for Tropical Diseases,
Assignment
Chi Minh City, Ho Chi Minh City, Vietnam
March 31, 2020
•Masking: None (Open Vietnam
Label)
•Cu Chi COVID Results First Posted:
•Primary Purpose: Hospital, No Results Posted
Treatment Vietnam
•Can Gio COVID Last Update Posted:
Outcome Measures: Hospital, March 31, 2020
•Viral clearance time Vietnam
•Lengh of hospital stay •Cho Ray
Hospital,
•Ventilator free days
Vietnam
•Oxygene free days
•National Hospital
•Time to death for Tropical
Diseases, Hanoi,
•Adverse events
Vietnam
•Time to viral PCR negative
•Department of
from rectal swab
Health, Ho Chi
•fever clearance time Minh city
•Ordinal outcome scale
•Development of ARDS
- Page 38 of 73 -
Collaborators Type
51 NCT04317040 CD24Fc as a Non-antiviral Title Acronym: Not yet •Severe Coronavirus •Drug: CD24Fc Study Type: Enrollment: •OncoImmune, •Industry Study Start: •Institute of Human Virology,
Immunomodulator in COVID-19 SAC-COVID recruiting Disease Interventional 230 Inc. May 2020 University of Maryland
•Drug: Placebo
Treatment (COVID-19) Baltimore, Baltimore, Maryland,
Other Ids: Phase: Age: Primary Completion: United States
Study Documents: CD24Fc-007 Phase 3 18 Years and older May 2021

(Adult, Older
Sex:
All First Posted:
Assignment
March 20, 2020

Treatment
March 23, 2020
Outcome Measures:
•Improvement of COVID-19
disease status
•Conversion rate of clinical
status at Day 8
•Conversion rate of clinical
status at Day 15
•Hospital discharge time
•All cause of death
ventilation
•Duration of pressors
•Duration of ECMO
•Duration of oxygen therapy
•Absolute lymphocyte count
- Page 39 of 73 -
Collaborators Type
52 NCT04288102 Treatment With Mesenchymal Title Acronym: Recruiting •Corona Virus •Biological: MSCs Study Type: Enrollment: •Beijing 302 •Other Study Start: •Maternal and Child Hospital of
Stem Cells for Severe Corona Disease Interventional 90 Hospital March 5, 2020 Hubei Province, Wuhan, Hubei,
•Biological: Saline
Virus Disease 2019(COVID-19) Other Ids: 2019(COVID-19) China
containing 1% •VCANBIO
2020-013-D Human serum Phase: Age: CELL & GENE Primary Completion: •Wuhan Huoshenshan Hospital,
Study Documents: albumin#solution of •Phase 1 18 Years to 75 ENGINEERING December 31, 2020 Wuhan, Hubei, China
MSC# Years (Adult, CORP.,LTD,
•Phase 2 China
Study Design: •Wuhan December 31, 2021
Sex: Huoshenshan
All Hospital, First Posted:
•Intervention Model: Parallel Wuhan, China
February 28, 2020
Assignment
•Maternal and
•Masking: Quadruple Child Health Results First Posted:
(Participant, Care Provider, Hospital of No Results Posted
Investigator, Outcomes Hubei Province
•Shenzhen
•Primary Purpose: Third People's March 23, 2020
Treatment Hospital
•Fifth Affiliated
Outcome Measures: Hospital,
•Size of lesion area and Sun Yat-Sen
severity of pulmonary University
fibrosis by chest CT
•Wuhan Union
•Proportion of patients Hospital, China
in each classification of
•West China
clinical critical treatment
Hospital
index
•Tianjin Haihe
•Oxygenation index( PaO2/
Hospital
FiO2)
•Duration of oxygen
therapy(days)
•Duration of
hospitalization(days)
•Blood oxygen saturation
•CD4+ T cell count and
cytokine level
•Side effects in the MSCs
treatment group
- Page 40 of 73 -
Collaborators Type
53 NCT04293692 Therapy for Pneumonia Patients Title Acronym: Withdrawn •COVID-19 •Biological: UC- Study Type: Enrollment: •Puren Hospital •Other Study Start: •Puren Hospital Affiliated to
iInfected by 2019 Novel MSCs Interventional 0 Affiliated February 24, 2020 Wuhan University of Science
Coronavirus Other Ids: to Wuhan and Technology, Wuhan,
•Other: Placebo
Pr20200225 Phase: Age: University of Primary Completion: Hubei, China
Science and
Study Documents: Not Applicable 18 Years to 75 Technology February 25, 2020
Years (Adult,
Study Design: Older Adult) •Wuhan Hamilton Study Completion:
Bio-technology
•Allocation: Randomized February 25, 2020
Sex: Co., Ltd
All First Posted:
Assignment
March 3, 2020
•Masking: Triple
Outcomes Assessor)
No Results Posted
•Primary Purpose:
March 18, 2020
Outcome Measures:
•Size of lesion area by
chest imaging
•Blood oxygen saturation
days
•Sequential organ failure
assessment
•Side effects in the UC-
MSCs treatment group
•Electrocardiogram, the
changes of ST-T interval
mostly
•Concentration of C-
reactive protein C-reactive
protein, immunoglobulin
•CD4+ and CD8+ T cells
count
•Concentration of the blood
cytokine (IL-1#, IL-6,
IL-8,IL-10,TNF-#)
•Concentration of the
myocardial enzymes
- Page 41 of 73 -
Collaborators Type
54 NCT04286503 The Clinical Study of Carrimycin Title Acronym: Not yet •Novel Coronavirus •Drug: Carrimycin Study Type: Enrollment: •Beijing YouAn •Other Study Start:
on Treatment Patients With recruiting Infectious Disease Interventional 520 Hospital February 23, 2020
•Drug: lopinavir/
COVID-19 Other Ids: (COVID-19)
ritonavir tablets •Shenyang
BeijingYouan or Arbidol or Phase: Age: Tonglian Group Primary Completion:
Study Documents: Hospital chloroquine Phase 4 18 Years to 75 Co., Ltd. February 28, 2021
•Study Protocol phosphate Years (Adult, •Institute of
•Drug: basic Study Design: Older Adult) Medicine and Study Completion:
•Informed Consent Form
treatment •Allocation: Randomized Biotechnology, February 28, 2021
Sex: Chinese
All Academy First Posted:
Assignment
of Medical
February 27, 2020
•Masking: None (Open Sciences
Label)
•Huangshi Results First Posted:
•Primary Purpose: Central Hospital No Results Posted
Treatment
•Shenyang
Pharmaceutical Last Update Posted:
Outcome Measures: University February 27, 2020
•Fever to normal time (day)
•First Affiliated
•Pulmonary inflammation Hospital of
resolution time (HRCT) Chongqing
(day) Medical
University
•Negative conversion (%) of
2019-nCOVRNA in gargle •The Second
(throat swabs) at the end Affiliated
of treatment Hospital of
Harbin Medical
University
•No.2 People's
Hospital of
Fuyang City
•First Affiliated
Hospital Bengbu
Medical College
•Renmin Hospital
of Wuhan
University
•The sixth
people's hospital
of Shenyang
•Nanyang Central
Hospital
- Page 42 of 73 -
Collaborators Type
55 NCT04328441 REDUCING HEALTH Title Acronym: Recruiting •COVID-19 •Drug: BCG Vaccine Study Type: Enrollment: •UMC Utrecht •Other Study Start: •Jeroen Bosch ziekenhuis, Den
CARE WORKERS BCG-CORONA Interventional 1000 March 25, 2020 Bosch, Brabant, Netherlands
•Radboud
ABSENTEEISM IN SARS-
University •Canisius Wilhelmina
CoV-2 PANDEMIC THROUGH Other Ids: Phase: Age: Primary Completion: Ziekenhuis, Nijmegen,
BACILLUS CALMETTE-
NL73249.041.20 Phase 3 18 Years and older October 25, 2020 Gelderland, Netherlands
GUÉRIN VACCINATION, A
RANDOMIZED CONTROLLED (Adult, Older •Radboud UMC, Nijmegen,
TRIAL Study Design: Adult) Study Completion: Gelderland, Netherlands
Sex: •Sint Maartenskliniek, Nijmegen,
Study Documents: •Intervention Model: Parallel Gelderland, Netherlands
All First Posted:
Assignment
March 31, 2020 •Noordwest Ziekenhuisgroep
•Masking: Quadruple locatie Alkmaar, Alkmaar,
(Participant, Care Provider, Noord Holland, Netherlands
No Results Posted •Hagaziekenhuis, Den Haag,
Assessor)
Zuid-Holland, Netherlands
•Primary Purpose: Last Update Posted: •Leiden University Medical
Prevention
March 31, 2020 Center, Leiden, Zuid-Holland,
Netherlands
Outcome Measures:
•Health Care Workers •Erasmus Medical Center,
absenteeism Rotterdam, Zuid-Holland,
Netherlands
•The cumulative incidence
of documented SARS- •University Medical Center
CoV-2 infection Utrecht, Utrecht, Netherlands
•The number of days of

unplanned absenteeism,
because of documented
SARS-CoV-2 infection
absenteeism, because of
imposed quarantine as
a result of exposure to
absenteeism, because of
imposed quarantine as
a result of having acute
respiratory symptoms,
fever or documented
unplanned absenteeism
because of self-reported
acute respiratory
symptoms
self-reported fever (#38 gr
C)
•The number of days
of self-reported acute
respiratory symptoms
of self-reported acute
of death for any reason
•and 6 more
- Page 43 of 73 -
Collaborators Type
56 NCT04329507 Non-invasive Detection Title Acronym: Not yet •COVID-19 •Diagnostic Test: Study Type: Enrollment: •NHS Lothian •Other Study Start:
of Pneumonia in Context recruiting Breath test Observational 200 March 25, 2020
•Respiratory
of Covid-19 Using Gas Other Ids: Disease
Chromatography - Ion Mobility 282014 Phase: Age: Primary Completion:
Spectrometry (GC-IMS)
Study Documents: •Observational Model: Adult) Study Completion:
Cohort March 25, 2020
Sex:
April 1, 2020
Outcome Measures:
•To perform a study in Results First Posted:
patients with clinical No Results Posted
features of pneumonia/
chest infection to identify Last Update Posted:
a signature of Covid-19
April 1, 2020
pneumonia in patients
exposed to SARS-CoV-2,
compared to unexposed
patients or those without.
•Detection of markers of
Covid-19 pneumonia
in non-invasive breath
samples.
•Relationship of this
biomarker signature to the
presence of SARS-CoV-2
in nasal and throat swabs.
•Subsequently, the
signature's relationship to
other biomarkers of SARS-
CoV-2 infection which are
currently being explored
•In a smaller group of
participants, ideally daily
non-invasive breath
samples will be collected
to determine if there are
changes between SARS-
CoV-2 positive patients
and those that are negative
until hospital discharge or
undue participant burden .
- Page 44 of 73 -
Collaborators Type
57 NCT04273321 Efficacy and Safety of Title Acronym: Recruiting •COVID-19 •Drug: Study Type: Enrollment: •Beijing Chao •Other Study Start: •Hubei province hospital of
Corticosteroids in COVID-19 Methylprednisolone Interventional 400 Yang Hospital February 14, 2020 integrated Chinese & Western
•Novel Coronavirus
Other Ids: Medicine, Wuhan, Hubei, China
Pneumonia
Study Documents: Methylprednisolone Phase: Age: Primary Completion: •Yichang first people's Hospital,
in COVID-19 Not Applicable 18 Years and older May 1, 2020 Yichang, Hubei, China
(Adult, Older •Beijing YouAn Hospital, Beijing,
Study Design: Adult) Study Completion: China
Sex: •Renmin Hospital of Wuhan
•Intervention Model: Single University, Wuhan, China
All First Posted:
Group Assignment
February 18, 2020 •Tianyou Hospital Affiliated to
•Masking: None (Open Wuhan University of science
Label) and technology, Wuhan, China
•Primary Purpose: No Results Posted •Union Hospital Affiliated to
Treatment Tongji Medical College of
Last Update Posted: Huazhong University of science
Outcome Measures: and technology, Wuhan, China
April 1, 2020
•the incidence of treatment •the first peopel hospital of
failure in 14 days Xiangyang, Xiangyang, China
•clinical cure incidence in
14 days
•the duration of virus
change to negative
•mortality at day 30
•ICU admission rate in 30
days
58 NCT04323345 Efficacy of Natural Honey Title Acronym: Not yet •COVID-19 •Dietary Study Type: Enrollment: •Misr University •Other Study Start: •Mahmoud Tantawy, Cairo,
Treatment in Patients With recruiting Supplement: Interventional 1000 for Science and March 25, 2020 Egypt
Novel Coronavirus Other Ids: Natural Honey Technology
MUST23032020 •Other: Standard Phase: Age: Primary Completion:
Study Documents: Care Phase 3 5 Years to 75 April 25, 2020
Years (Child,
Sex:
All First Posted:
Assignment
March 26, 2020
•Masking: Single
(Investigator)
Treatment
Last Update Posted:
Outcome Measures:
March 26, 2020
•Rate of recovery from
positive to negative swaps
•Fever to normal
temperature in days
•Resolution of lung
inflammation in CT or X ray
•30 days mortality rate
•Number of days till
reaching negative swab
results
- Page 45 of 73 -
Collaborators Type
59 NCT04318444 Hydroxychloroquine Post Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •Columbia •Other Study Start: •Columbia University Irving
Exposure Prophylaxis recruiting Hydroxychloroquine Interventional 1600 University March 2020 Medical Center, New York,
•Corona Virus
for Coronavirus Disease Other Ids: New York, United States
Infection •Drug: Placebo oral
(COVID-19) AAAS9676 Phase: Age: Primary Completion:
tablet
•Phase 2 18 Years and older March 2021
•Phase 3
Adult) Study Completion:
Study Design: March 2022
Sex:
All First Posted:
Assignment
Prevention
Outcome Measures:
Number of participants with
symptomatic, lab-confirmed
COVID-19.
60 NCT04318015 Hydroxychloroquine Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •National Institute •Other Study Start:
Chemoprophylaxis in Healthcare PHYDRA recruiting Hydroxychloroquine Interventional 400 of Respiratory April 1, 2020
•Severe Acute •Industry
Personnel in Contact With Diseases,
Respiratory •Drug: Placebo oral
COVID-19 Patients (PHYDRA Other Ids: Phase: Age: Mexico Primary Completion:
Syndrome tablet
Trial)
ProfilaxisCOVID Phase 3 18 Years and older •Sanofi December 31, 2020
(Adult, Older
Study Documents: Study Design: Adult) Study Completion:
Sex:
All First Posted:
Assignment
March 23, 2020

Prevention
March 23, 2020
Outcome Measures:
•Symptomatic COVID-19
infection rate
•Symptomatic non-COVID
viral infection rate
•Days of labor absenteeism
•Rate of labor absenteeism
•Rate of severe respiratory
COVID-19 disease in
healthcare personnel
- Page 46 of 73 -
Collaborators Type
61 NCT04328272 Effectiveness of Title Acronym: Not yet •COVID19 •Drug: Study Type: Enrollment: •Prof. Dr. Umar •Other Study Start: •Ayub Teaching Institution,
Hydroxychloroquine in Covid-19 Covid recruiting Hydroxychloroquine Interventional 75 Farooq March 28, 2020 Abbott#b#d, K.p.k, Pakistan
Patients 200 Mg Oral Tablet
•Ayub Medical
Other Ids: Phase: Age: College, Primary Completion:
Study Documents: Ath/ct101/22/3 Phase 3 18 Years to 50 Abbottabad May 28, 2020
Years (Adult)
•Allocation: Randomized Sex: June 28, 2020
All
Assignment First Posted:
March 31, 2020
•Masking: Single
(Participant)
Treatment
Last Update Posted:
Outcome Measures:
March 31, 2020
•National Early Warning
Score equal to zero
•C-reactive proteins
•Lymphocyte Count
•d-dimers
62 NCT04327531 Evaluation of Covid 19 Title Acronym: Active, not •COVID-19 •Behavioral: turkish Study Type: Enrollment: •Kanuni Sultan •Other Study Start: •Pinar Yalcin Bahat, Istanbul,
Knowledge Anxiety and recruiting physicians Observational 200 Suleyman March 26, 2020 ##stanbul, Turkey
•Physician-Patient
Expectation Levels of Turkish Other Ids: Training and
Relations
Physicians, Survey Study turkishcovid19 Phase: Age: Research Primary Completion:
Hospital
25 Years to 55 April 26, 2020
Study Documents: Study Design: Years (Adult)
Ecologic or Community Sex: April 28, 2020
Prospective First Posted:
March 31, 2020
Outcome Measures:
Evaluation of covid-19 Results First Posted:
knowledge level of turkish No Results Posted
physicians
Last Update Posted:
March 31, 2020
- Page 47 of 73 -
Collaborators Type
63 NCT04323644 Outcomes of Surgery Title Acronym: Not yet •COVID-19 •Procedure: Surgery Study Type: Enrollment: •University of •Other Study Start:
in COVID-19 Infection: CovidSurg recruiting Observational 1000 Birmingham March 31, 2020
•Coronavirus
International Cohort Study
(CovidSurg) Other Ids: •Surgery Phase: Age: Primary Completion:
CS-20200324 Child, Adult, Older September 30, 2020
Study Documents: Study Design: Adult
Cohort Sex: September 30, 2020
•Time Perspective: Other All
First Posted:
Outcome Measures: March 26, 2020
•30-day mortality
•7-day mortality
No Results Posted
•30-day reoperation
•Postoperative ICU Last Update Posted:
admission March 26, 2020
•Postoperative respiratory
failure
•Postoperative acute
respiratory distress
syndrome (ARDS)
•Postoperative sepsis
64 NCT04251767 Washed Microbiota Title Acronym: Withdrawn •COVID-19 •Other: washed Study Type: Enrollment: •The Second •Other Study Start: •Medical Center for Digestive
Transplantation for Patients With Complicated microbiota Interventional 0 Hospital of February 5, 2020 Diseases, The Second
2019-nCoV Infection Other Ids: With Refractory transplantation Nanjing Medical Affiliated Hospital of Nanjing
WMT-YJ-202001 Intestinal Infections Phase: Age: University Primary Completion: Medical University, Nanjing,
•Other: placebo
Jiangsu, China
Study Documents: Not Applicable 14 Years to 70 April 30, 2020
Years (Child,
•Allocation: Randomized April 30, 2020
Sex:
All First Posted:
Assignment
February 5, 2020

Treatment
March 17, 2020
Outcome Measures:
Number of participants with
improvement from severe
type to common type
- Page 48 of 73 -
Collaborators Type
65 NCT04330144 Hydroxychloroquine as Post Title Acronym: Not yet •Contact Person •Drug: Study Type: Enrollment: •Gangnam •Other Study Start:
Exposure Prophylaxis for SARS- recruiting From COVID-19 Hydroxychloroquine Interventional 2486 Severance April 1, 2020
CoV-2(HOPE Trial) Other Ids: Confirmed Patient as post exposure Hospital
3-2020-0036 prophylaxis Phase: Age: Primary Completion:
Study Documents: •Other: Others(No Phase 3 18 Years to 99 March 30, 2021
intervention) Years (Adult,
Sex:
All First Posted:
Assignment
April 1, 2020
•Masking: Single
(Outcomes Assessor)
Prevention
Last Update Posted:
Outcome Measures:
April 1, 2020
The rate of COVID-19
66 NCT04299724 Safety and Immunity of Covid-19 Title Acronym: Recruiting •Treat and Prevent •Biological: Study Type: Enrollment: •Shenzhen Geno- •Other Study Start: •Shenzhen Geno-immune
aAPC Vaccine Covid-19 Infection Pathogen-specific Interventional 100 Immune Medical February 15, 2020 Medical Institute, Shenzhen,
Other Ids: aAPC Institute Guangdong, China
Study Documents: GIMI-IRB-20002 Phase: Age: •Shenzhen Primary Completion:

Phase 1 6 Months to 80 Third People's July 31, 2023
Years (Child, Hospital
Study Design: Adult, Older Adult) •Shenzhen Study Completion:
•Intervention Model: Single Second People's December 31, 2024
Group Assignment Sex: Hospital
All First Posted:
•Primary Purpose:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•Frequency of vaccine
events March 9, 2020
vaccine events
•Proportion of subjects with
positive T cell response
•28-day mortality
ventilation if applicable
•Proportion of patients in
each category of the 7-
point scale
normalized inflammation
factors
•Clinical improvement
based on the 7-point scale
if applicable
•Lower Murray lung injury
score if applicable
- Page 49 of 73 -
Collaborators Type
67 NCT04298814 Safety Related Factors of Title Acronym: Not yet •COVID-19 •Other: severe Study Type: Enrollment: •Tongji Hospital •Other Study Start:
Endotracheal Intubation in recruiting covid-19 Observational 120 March 7, 2020
•Endotracheal
Patients With Severe Covid-19 Other Ids: pneumonia with ET
Intubation
Pneumonia COVEI Phase: Age: Primary Completion:
18 Years to 90 May 30, 2020
Case-Only July 30, 2020
Sex:
March 6, 2020
Outcome Measures:
•Success rate of intubation Results First Posted:
•Infection rate of No Results Posted
Anesthesiologist
Last Update Posted:
•Extubation time
March 6, 2020
68 NCT04324190 DIgital Online SuPport for Title Acronym: Not yet •COVID-19 •Behavioral: Guided Study Type: Enrollment: •Gunther •Other Study Start: •Selfapy GmbH, Berlin,
COVID-19 StrEss DISPOSE recruiting online support Interventional 600 Meinlschmidt March 2020 Germany
•Psychosocial
program
Stress •Selfapy GmbH
Study Documents: Other Ids: •Behavioral: WHO Phase: Age: Primary Completion:
•Mental Health •International
IPUB_2020_01 recommendations Not Applicable 18 Years and older June 2021
Psychoanalytic
(waiting condition) (Adult, Older University Berlin
Sex:
All First Posted:
March 27, 2020
•Masking: Single (Care
Provider)
Treatment
Last Update Posted:
Outcome Measures:
March 27, 2020
•Change in Short-Form-36
(SF-36) Health Survey -
Mental Health Component
Summary score
•Chronic stress items (9
items)
•Generalized Anxiety
Disorder Scale (GAD-7)
•Patient Health
Questionnaire (PHQ8)
•Somatic Symptom
Disorder (SSD-12)
•Somatic Symptom Scale
(SSS-8)
•Screening Tool for
Psychological Distress
(STOP-D) - selected items
- Page 50 of 73 -
Collaborators Type
69 NCT04276896 Immunity and Safety of Covid-19 Title Acronym: Recruiting •Pathogen Infection •Biological: Injection Study Type: Enrollment: •Shenzhen Geno- •Other Study Start: •Shenzhen Geno-immune
Synthetic Minigene Vaccine Covid-19 Infection and infusion of Interventional 100 Immune Medical March 24, 2020 Medical Institute, Shenzhen,
Other Ids: LV-SMENP- Institute Guangdong, China
GIMI-IRB-20001 DC vaccine and Phase: Age: Primary Completion:
Study Documents: •Shenzhen •Shenzhen Second People's
antigen-specific
•Phase 1 6 Months to 80 Third People's July 31, 2023 Hospital, Shenzhen,
CTLs
Years (Child, Hospital Guangdong, China
•Phase 2
Adult, Older Adult) •Shenzhen Study Completion: •Shenzhen Third People's
Study Design: Second People's December 31, 2024 Hospital, Shenzhen,
Sex: Hospital Guangdong, China
All First Posted:
Group Assignment
February 19, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 19, 2020
•Clinical improvement
based on the 7-point scale
•Lower Murray lung injury
score
•28-day mortality
ventilation
negative RT-PCR results
•Proportion of patients in
each category of the 7-
point scale
normalized inflammation
factors
•Frequency of vaccine/CTL
Events
•Frequency of Serious
vaccine/CTL Events
- Page 51 of 73 -
Collaborators Type
70 NCT04326725 Proflaxis Using Title Acronym: Recruiting •to Evaluate •Drug: Plaquenil Study Type: Enrollment: •Istinye University •Other Study Start: •Istinye University Medical
Hydroxychloroquine Plus the Efficacy of 200Mg Tablet Observational 80 March 20, 2020 School, Istanbul, Turkey
Vitamins-Zinc During COVID-19 Other Ids: Hydroxychloroquine
Pandemia 2020-2/1 Plus vitACD-Zinc Phase: Age: Primary Completion:
as Prevention for
COVID19 Infection 20 Years to 90 July 1, 2020
Case-Control September 1, 2020
Sex:
March 30, 2020
Outcome Measures:
Protection against Results First Posted:
COVID-19 No Results Posted
Last Update Posted:

March 30, 2020
71 NCT04328961 Hydroxychloroquine for Title Acronym: Not yet •COVID-19 •Drug: Study Type: Enrollment: •University of •Other Study Start: •NYU Langone Health, New
COVID-19 PEP recruiting Hydroxychloroquine Interventional 2000 Washington March 2020 York, New York, United States
•Corona Virus
Other Ids: Sulfate
Infection •New York •University of Washington,
Study Documents: STUDY00009750 •Drug: Ascorbic Acid Phase: Age: University Primary Completion: Coordinating Center, Seattle,
•SARS (Severe
Phase 1 18 Years to 80 September 30, 2020 Washington, United States
Acute Respiratory •Bill and
Syndrome) Years (Adult, Melinda Gates •UW Virology Research Clinic,
Study Design: Older Adult) Foundation Study Completion: Seattle, Washington, United
•Allocation: Randomized October 31, 2020 States
Sex:
All First Posted:
Assignment
April 1, 2020
•Masking: Single
(Participant)
Prevention
Last Update Posted:
Outcome Measures:
April 1, 2020
•Polymerase chain reaction
(PCR) confirmed SARS-
CoV-2 infection
•Rate of participant-
reported adverse events
•Incidence rates of
COVID-19 through study
completion
- Page 52 of 73 -
Collaborators Type
72 NCT04323514 Use of Ascorbic Acid in Patients Title Acronym: Recruiting •Hospitalized •Dietary Study Type: Enrollment: •University of •Other Study Start: •A.R.N.A.S. Civico - Di Cristina -
With COVID 19 Patients With Supplement: Interventional 500 Palermo March 13, 2020 Benfratelli, Palermo, Italy
Other Ids: Covid-19 Vitamin C
3143 Pneumonia Phase: Age: Primary Completion:
Study Documents:
•Study Protocol, Statistical Not Applicable Child, Adult, Older March 13, 2021
Analysis Plan, and Informed Adult
Consent Form Study Design: Study Completion:
•Intervention Model: Single Sex: March 13, 2021
•Primary Purpose:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•In-hospital mortality
March 26, 2020
•PCR levels
•Lactate clearance
•Hospital stay
•Symptoms
•Positive swab
•Tomography imaging
73 NCT04322188 An Observational Case-control Title Acronym: Recruiting •Severe Acute Study Type: Enrollment: •A.O. Ospedale •Other Study Start: •ASST - Papa Giovanni XXIII,
Study of the Use of Siltuximab in SISCO Respiratory Observational 50 Papa Giovanni March 19, 2020 Bergamo, Italy
ARDS Patients Diagnosed With Syndrome (ARDS) XXIII
COVID-19 Infection Other Ids: Secondary to Phase: Age: Primary Completion:
SARS-COV-2
v 0.9 16th March Infection 18 Years and older May 19, 2020
Study Documents: 2020 Study Design: (Adult, Older
Case-Control May 19, 2020
Sex:
March 26, 2020
Outcome Measures:
•Cohort A: reduction of the Results First Posted:
need of invasive ventilation No Results Posted
or 30-day mortality
•Cohort B: reduction of Last Update Posted:
mortality March 31, 2020
•Cohort A Reduction of the
need of time of ventilatory
support
•Cohort B Percentage of
patients that undergo to
tracheostomy
•Cohort B Improvement of
the lung function assessed
by radiologic findings
- Page 53 of 73 -
Collaborators Type
74 NCT04318431 Prevalence of SARS -Cov2 Title Acronym: Not yet •Covid19 •Diagnostic Test: Study Type: Enrollment: •Centre •Other Study Start: •Cabinet du Dr Belaroussi,
Carriage in Asymptomatic and COVILLE recruiting Data collection and Interventional 600 Hospitalier April 2020 Boulogne, France
Mildly-symptomatic Children rhinopharyngeal Intercommunal
•Cabinet du Dr Derkx,
Other Ids: swab Phase: Age: Creteil Primary Completion: Champigny-sur-Marne, France
Study Documents: •COVILLE Not Applicable 6 Months to 15 •ACTIV June 2020 •Cabinet du Dr Coicadan,
Years (Child) Chennevières-sur-Marne,
•2020-A00724-35
Study Design: Study Completion: France
•Intervention Model: Single Sex: June 2020
•Cabinet du Dr Corrard, Combs-
la-Ville, France
March 24, 2020 •53 Boulevard De La Liberté,
Label)
Les Lilas, France
•Primary Purpose:
Results First Posted: •157 Avenue du Général
Diagnostic
No Results Posted Leclerc, Maisons-Alfort, France
Outcome Measures: •Cabinet du Dr Bodin,
Last Update Posted: Montgeron, France
•Proportion of
asymptomatic children March 26, 2020
•Cabinet du Dr Deberdt, Nogent-
or children with mild sur-Marne, France
•Cabinet du Dr Wollner, Nogent-
•Confirmed Cov2-SARS sur-Marne, France
cases by age
•Cabinet du Dr D'acremont,
•Confirmed Cov2-SARS Paris, France
cases by symptoms
•and 6 more
•Viral load
•Other respiratory viruses
75 NCT04316299 Acute Kidney Injury in Patients Title Acronym: Completed •COVID-19 Study Type: Enrollment: •Zhenhua Zen •Other Study Start: •Hankou Hospital, Wuhan,
Hospitalized With COVID-19 Observational 287 February 26, 2020 Hubei, China
•Acute Kidney Injury •Nanfang
Other Ids: Hospital of
hkyy2020-005 AKI •Kidney Function Phase: Age: Primary Completion:
Study Documents: Southern
18 Years and older Medical February 28, 2020
Study Design: (Adult, Older University
Sex:
March 20, 2020
Outcome Measures:
•Rate of Acute Kidney Injury Results First Posted:
•Rate of Death No Results Posted
•the length of hospital stay Last Update Posted:

March 30, 2020
- Page 54 of 73 -
Collaborators Type
76 NCT04320017 Joint Use of Electrocardiogram Title Acronym: Recruiting •COVID-19 •Diagnostic Test: Study Type: Enrollment: •Groupe •Other Study Start: •Clinical Investigation Center
and Transthoracic JOCOVID Electrocardiogram Observational 500 Hospitalier Pitie- March 20, 2020 Pitié-Salpêtrière, Paris, France
•Myocardial Injury
Echocardiography in an and transthoracic Salpetriere
Observational Study to Monitor Other Ids: •Myocarditis echocardiography Phase: Age: Primary Completion:
Cardio-vascular Events in
Patients Diagnosed With CIC1421-20-05 16 Years and older May 20, 2020
Study Design: (Child, Adult,
COVID-19
Cohort May 20, 2020
Study Documents: Sex:
March 24, 2020
Outcome Measures:
•Incidence of acute Results First Posted:
myocardial events in No Results Posted
COVID-19 population
at baseline and during Last Update Posted:
hospital stay
March 24, 2020
•Description of
cardiovascular outcomes in
the cohort
•Prognosis role of
baseline cardio-vascular
caracteristics on patients
survival
•Prediction of cardio-
vascular events with
baseline characteristics
•Characterization of
inflammation on cardio-
vascular outcomes
- Page 55 of 73 -
Collaborators Type
77 NCT04313127 A Phase I Clinical Trial in 18-60 Title Acronym: Active, not •COVID-19 •Biological: Study Type: Enrollment: •CanSino •Industry Study Start: •Hubei Provincial Center
Adults APICTH recruiting Recombinant Interventional 108 Biologics Inc. March 16, 2020 for Disease Control and
•Other
Novel Coronavirus Prevention, Wuhan, Hubei,
•Institute of
Other Ids: Vaccine Phase: Age: Primary Completion: China
Study Documents: Biotechnology,
(Adenovirus Type 5
JSVCT088 Phase 1 18 Years to 60 Academy of December 30, 2020
Vector)
Years (Adult) Military Medical
Study Design: Sciences. PLA Study Completion:
Sex: of China
•Allocation: Non- December 20, 2022
Randomized All •Jiangsu
Province First Posted:
Centers for
Sequential Assignment March 18, 2020
Disease Control
•Masking: None (Open and Prevention
Label)
•Hubei Provincial No Results Posted
•Primary Purpose: Center for
Prevention Disease Control
Last Update Posted:
and Prevention
March 31, 2020
Outcome Measures: •Tongji Hospital
•Safety indexes of adverse
reactions
•Safety indexes of adverse
events
•Safety indexes of SAE
•Safety indexes of lab
measures
•Immunogencity indexes of
GMT(ELISA)
•Immunogencity indexes
of GMT(pseudoviral
neutralization test method)
seropositivity rates(ELISA)
of seropositivity
rates(pseudoviral
GMI(ELISA)
of GMI(pseudoviral
•and 3 more
- Page 56 of 73 -
Collaborators Type
78 NCT04328012 Comparison Of Therapeutics Title Acronym: Not yet •SARS-CoV-2 •Drug: lopinavir/ Study Type: Enrollment: •Bassett •Other Study Start:
for Hospitalized Patients COVID MED recruiting Infection ritonavir Interventional 4000 Healthcare April 1, 2020
Infected With SARS-CoV-2
•Drug:
In a Pragmatic aDaptive Other Ids: Phase: Age: Primary Completion:
Hydroxychloroquine
randoMizED Clinical Trial
1581969 Sulfate •Phase 2 18 Years and older January 1, 2021
During the COVID-19 Pandemic
(COVID MED Trial) •Drug: Losartan (Adult, Older
•Phase 3
•Drug: Placebos
Study Design: April 1, 2021
Study Documents: Sex:
All First Posted:
Assignment
Treatment
Outcome Measures:
•NIAID COVID-19 Ordinal
Severity Scale (NCOSS)
•Hospital length of stay
(LOS)
•ICU level LOS
•Mechanical ventilation
•survival
- Page 57 of 73 -
Collaborators Type
79 NCT04330599 Longitudinal Population- Title Acronym: Not yet •COVID-19 Study Type: Enrollment: •Queen Mary •Other Study Start:
based Observational Study of COVIDENCE recruiting Observational 12000 University of April 2, 2020
Coronavirus Disease in the UK London
Population Other Ids: Phase: Age: Primary Completion:
•King's College
COVIDENCE 16 Years and older London April 1, 2025
Study Documents: Study Design: (Child, Adult, •London School
•Observational Model: Older Adult) of Hygiene Study Completion:
Cohort and Tropical April 1, 2025
Sex: Medicine
April 1, 2020
Outcome Measures:
•Incidence of suspected, Results First Posted:
probable or confirmed No Results Posted
COVID-19
•Incidence of confirmed Last Update Posted:
COVID-19 April 1, 2020
•Incidence of COVID-19
requiring hospitalisation
•Incidence of COVID-19
requiring ventilatory
support
•Incidence of fatal
COVID-19
•Symptom duration per
COVID-19 episode
•Symptom severity per
COVID-19 episode
•Incidence of
seroconversion to SARS-
CoV-2
•Incidence of recurrent
COVID-19
•EQ-5D-3L health-related
quality of life score
•and 4 more
- Page 58 of 73 -
Collaborators Type
80 NCT04328480 The ECLA PHRI COLCOVID Title Acronym: Not yet •COVID-19 •Drug: Colchicine Study Type: Enrollment: •Estudios •Other Study Start:
Trial COLCOVID recruiting Interventional 2500 Clínicos Latino March 2020
•Other: Local
América
standard of care
Study Documents: Other Ids: Phase: Age: •Population Primary Completion:
COLCOVID Phase 3 18 Years and older Health Research May 30, 2020
version1.2 (Adult, Older Institute
Sex:
All First Posted:
Assignment
March 31, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 31, 2020
•All-cause mortality
•Composite
outcome:composite of
intubation for mechanical
ventilation or death.
81 NCT04311398 Development and Verification Title Acronym: Not yet •COVID-19 •Diagnostic Test: Study Type: Enrollment: •Huashan •Other Study Start: •Huashan Hospital of Fudan
of a New Coronavirus Multiplex recruiting New QIAstat-Dx Observational 100 Hospital March 14, 2020 University, Shanghai,
Nucleic Acid Detection System Other Ids: fully automatic Shanghai, China
KY2020-COVID-19 multiple PCR Phase: Age: Primary Completion:
detection platform
Study Documents: 16 Years to 100 June 1, 2020
Study Design: Years (Child,
•Observational Model: Adult, Older Adult) Study Completion:
Cohort December 1, 2020
Sex:
March 17, 2020
Outcome Measures:
Sensitivity# spectivity Results First Posted:
turnaround time of the New No Results Posted
QIAstat-Dx fully automatic
multiple PCR detection Last Update Posted:
platform
March 17, 2020
- Page 59 of 73 -
Collaborators Type
82 NCT04310228 Favipiravir Combined With Title Acronym: Recruiting •COVID-19 •Drug: Favipiravir Study Type: Enrollment: •Peking •Other Study Start: •Anhui Medical University
Tocilizumab in the Treatment of Combined With Interventional 150 University First March 8, 2020 Affiliated First Hospital, Hefei,
Corona Virus Disease 2019 Other Ids: Tocilizumab Hospital Anhui, China
2020YFC0844100 •Drug: Favipiravir Phase: Age: Primary Completion: •Guiqiang Wang, Beijing,
Study Documents: Not Applicable 18 Years to 65 May 2020 Beijing, China
•Drug: Tocilizumab
Years (Adult, •Peking University First Hospital,
Study Design: Older Adult) Study Completion: Beijing, Beijing, China
Sex: •Cancer Hospital Union Hospital
•Intervention Model: Parallel Tongji Medical College
All First Posted:
Assignment Huazhong University of
March 17, 2020 Science and Technology,
Wuhan, Hubei, China
Label)
•Ezhou Central Hospital,
•Primary Purpose: No Results Posted Wuhan, Hubei, China
Treatment
Last Update Posted: •Huoshenshan Hospital of
Outcome Measures: Wuhan, Wuhan, Hubei, China
March 17, 2020
•Clinical cure rate •Jinyintan Hospital of Wuhan,
Wuhan, Hubei, China
•Viral nucleic acid test
negative conversion rate •Tongji Hospital of Huazhong
and days from positive to University of Science and
negative Technology, Wuhan, Hubei,
China
•Duration of fever
•West Hospital Union Hospital
•Lung imaging improvement
Huazhong University of
time
Science and Technology,
•Mortality rate because Wuhan, Hubei, China
of Corona Virus Disease
•Wuhan Pulmonary Hospital,
2019
Wuhan, Hubei, China
•Rate of non-invasive
•Zhongnan Hospital of Wuhan
or invasive mechanical
University, Wuhan, Hubei,
ventilation when
China
respiratory failure occurs
•Mean in-hospital time
83 NCT04302519 Novel Coronavirus Induced Title Acronym: Not yet •COVID-19 •Biological: Dental Study Type: Enrollment: •CAR-T •Industry Study Start:
Severe Pneumonia Treated by recruiting pulp mesenchymal Interventional 24 (Shanghai) March 5, 2020
Dental Pulp Mesenchymal Stem Other Ids: stem cells Biotechnology
Cells KT005HB001 Phase: Age: Co., Ltd. Primary Completion:
Early Phase 1 18 Years to 75 June 30, 2021
•Intervention Model: Single July 30, 2021
All First Posted:
•Primary Purpose:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•Disppear time of ground-
glass shadow in the lungs March 10, 2020
•Absorption of Lung shadow

absorption by CT Scan-
Chest
•Changes of blood oxygen
- Page 60 of 73 -
Collaborators Type
84 NCT04295551 Multicenter Clinical Study on the Title Acronym: Not yet •COVID-19 •Drug: Lopinavir / Study Type: Enrollment: •Jiangxi Qingfeng •Industry Study Start:
Efficacy and Safety of Xiyanping recruiting ritonavir tablets Interventional 80 Pharmaceutical March 14, 2020
Injection in the Treatment of Other Ids: combined with Co. Ltd.
New Coronavirus Infection QF-XYP1990-1 Xiyanping injection Phase: Age: Primary Completion:
Pneumonia (General and
•Drug: Lopinavir/ Not Applicable 18 Years to 100 July 14, 2020
Severe)
ritonavir treatment Years (Adult,
Study Documents:
•Allocation: Randomized April 14, 2021
Sex:
All First Posted:
Assignment
March 4, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 4, 2020
Clinical recovery time
85 NCT04321265 Outcomes and Prognostic Title Acronym: Recruiting •COVID-19 Study Type: Enrollment: •Heinrich-Heine •Other Study Start: •Division of Cardiology,
Factors in COVID-19 COVIP Observational 4000 University, March 19, 2020 Pulmonary Disease
•Elderly Patients
Duesseldorf and Vascular Medicine,
Other Ids: •Critical Illness Phase: Age: Primary Completion: Duesseldorf, Germany
Study Documents:
20-004 •Survival 70 Years and older September 2020
Study Design: (Older Adult)
•Old Age
Cohort Sex: December 2020
Prospective First Posted:
March 25, 2020
Outcome Measures:
•Survival Results First Posted:
•Fragilty No Results Posted
Last Update Posted:

March 27, 2020
- Page 61 of 73 -
Collaborators Type
86 NCT04326790 The GReek Study in the Effects Title Acronym: Not yet •Corona Virus •Drug: Colchicine Study Type: Enrollment: •National and •Other Study Start:
of Colchicine in Covid-19 GRECCO-19 recruiting Disease 19 (Covid Interventional 180 Kapodistrian April 6, 2020
•Drug: Standard
cOmplications Prevention 19) University of
treatment
Other Ids: Phase: Age: Athens Primary Completion:
Study Documents: 906295542 Phase 2 18 Years and older August 31, 2020
(Adult, Older
Sex:
All First Posted:
Assignment
March 30, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
April 1, 2020
•CRP increase to 3 x upper
limit of normal
•Clinical deterioration in the
semiquantitative ordinal
scale suggested by the
WHO R&D committee
•Maximal concentration of
cardiac troponin
- Page 62 of 73 -
Collaborators Type
87 NCT04327206 BCG Vaccination to Protect Title Acronym: Not yet •Coronavirus •Drug: BCG Vaccine Study Type: Enrollment: •Murdoch •Other Study Start: •Royal Children's Hospital,
Healthcare Workers Against BRACE recruiting Disease 2019 Interventional 4170 Childrens March 30, 2020 Melbourne, Victoria, Australia
COVID-19 (COVID-19) Research
Other Ids: Phase: Age: Institute Primary Completion:
•Febrile Respiratory
Study Documents: 62586 Illness Phase 3 18 Years and older •Royal Children's October 30, 2020
(Adult, Older Hospital
•Corona Virus
Infection Study Design: Adult) Study Completion:
•COVID-19 Sex:
All First Posted:
Assignment
March 31, 2020
Label)
Prevention
Last Update Posted:
Outcome Measures:
March 31, 2020
•COVID-19 disease
incidence
•Severe COVID-19 disease
incidence
•COVID-19 incidence by 12
months
•Severe COVID-19
incidence by 12 months
•Time to first symptom of
COVID-19
•Episodes of COVID-19
•Asymptomatic SARS-
CoV-2 infection
•Work absenteeism due to
COVID-19
•Bed confinement due to
COVID-19
•Symptom duration of
COVID-19
•and 22 more
- Page 63 of 73 -
Collaborators Type
88 NCT04325646 Sero-epidemiological Study Title Acronym: Recruiting •SARS (Severe •Other: Human Study Type: Enrollment: •Institut Pasteur •Industry Study Start: •CHU Amiens-Picardie, Amiens,
of the SARS-CoV-2 Virus CORSER Acute Respiratory Biological samples Observational 1000 March 13, 2020 France
in France: Constitution of a Syndrome)
•CHU François Mitterand, Dijon,
Collection of Human Biological Other Ids: Phase: Age: Primary Completion:
•COVID-19 France
Samples
2020-007 5 Years and older February 28, 2021 •CHU Limoges, Limoges,
Study Design: (Child, Adult, Older France
Study Documents: •Observational Model: Adult) Study Completion:
Cohort •Hôpital de la Croix Rousse,
February 28, 2023
Sex: Lyon, France
Prospective All First Posted: •Hôpitaux de Brabois, Nancy,
March 27, 2020 France
Outcome Measures: •CHR Orléans, Orléans, France
•Presence of specific anti- Results First Posted:
•Institut Pasteur, Paris, France
SARS-CoV-2 antibodies in No Results Posted
the different study groups. •CHU Poitiers, Poitiers, France
•Percentage of Last Update Posted: •Hôpital Pontchaillou, Rennes,
asymptomatic forms in March 31, 2020 France
individuals with anti-SARS-
•CHU Saint-Etienne, Saint-
CoV-2 antibodies
Étienne, France
•CH de Tourcoing, Tourcoing,
France
•Hôpital Bretonneau, Tours,
France
89 NCT04292964 Prognostic Factors of Patients Title Acronym: Completed •SARS-CoV-2 Study Type: Enrollment: •Chongqing •Other Study Start: •The First Affiliated Hospital of
With COVID-19 Observational 201 Medical March 1, 2020 Chongqing Medical University,
•Outcome, Fatal
Other Ids: University Chongqing, China
Study Documents: 2020-02-2 Phase: Age: Primary Completion:

Cohort March 13, 2020
Sex:
March 3, 2020
Outcome Measures:
•all-cause mortality Results First Posted:
•Severe state No Results Posted
Last Update Posted:

March 17, 2020
- Page 64 of 73 -
Collaborators Type
90 NCT04278963 Yinhu Qingwen Decoction for Title Acronym: Active, not •CoVID-19 •Drug: YinHu Study Type: Enrollment: •China Academy •Other Study Start: •Jingzhou Hospital of Traditional
the Treatment of Mild / Common recruiting QingWen Interventional 300 of Chinese February 27, 2020 Chinese Medicine, Jingzhou,
•Chinese Medicine
CoVID-19 Other Ids: Decoction Medical Hubei, China
YHQW-V3.0 Phase: Age: Sciences Primary Completion:
•Drug: YinHu •Wuhan Leishenshan (Thunder
Study Documents: QingWen •Phase 2 18 Years and older January 2021 God Mountain) Hospital/The
Decoction(low (Adult, Older First Affiliated Hospital of
dose) •Phase 3 Dalian Medical University,
Wuhan, Hubei, China
•Other: Chinese Study Design: January 2021
medicine treatment Sex: •Xiangyang Hospital of
All First Posted: Traditional Chinese Medicine,
•Other: standard
•Intervention Model: Parallel Xiangyang, Hubei, China
western medicine February 20, 2020
Assignment
treatment
•Masking: Double Results First Posted:
(Participant, Outcomes No Results Posted
Assessor)
Treatment March 17, 2020
Outcome Measures:
•Mean clinical recovery time
(hours)
•Time to CoVID-19 RT-
PCR negative in upper
respiratory tract specimen
•Change (reduction) in
CoVID-19 viral load in
upper respiratory tract
specimen as assessed by
area under viral load curve.
(in those with fever at
enrolment)
•Time to cough reported as
mild or absent (in those
with cough at enrolment
rated severe or moderate)
•Time to dyspnea reported
as mild or absent (on a
scale of severe, moderate,
mild absent, in those with
dyspnea at enrollment
rated as severe or
moderate)
•Frequency of requirement
for supplemental oxygen or
non-invasive ventilation
•Frequency of respiratory
progression
•Severe case incidence
•Proportion of re-
hospitalization or
admission to ICU
•All-cause mortality
adverse events
- Page 65 of 73 -
Collaborators Type
91 NCT04303507 Chloroquine/ Title Acronym: Not yet •COVID19 •Drug: Study Type: Enrollment: •University of •Other Study Start:
Hydroxychloroquine Prevention COPCOV recruiting Chloroquine or Interventional 40000 Oxford April 2020
•Coronavirus
of Coronavirus Disease Hydroxychloroquine
(COVID-19) in the Healthcare Other Ids: •Acute Respiratory Phase: Age: Primary Completion:
•Drug: Placebo
Setting Illnesses
VIR20001 Not Applicable 16 Years and older April 2021
(Child, Adult,
Study Documents: Study Design: Older Adult) Study Completion:
•Allocation: Randomized April 2021
Sex:
All First Posted:
Assignment
March 11, 2020
•Masking: Double
(Participant, Investigator)
Prevention
Last Update Posted:
Outcome Measures:
March 27, 2020
•Number of symptomatic
COVID-19 infections
•Symptoms severity of
COVID-19
•Number of asymptomatic
cases of COVID-19
•Number of symptomatic
acute respiratory illnesses
•Severity of symptomatic
acute respiratory illnesses
92 NCT04272710 Prognositc Factors in COVID-19 Title Acronym: Withdrawn •2019-nCoV Study Type: Enrollment: •Chongqing •Other Study Start: •The First Affiliated Hospital of
Patients Complicated With Observational 0 Medical January 25, 2020 Chongqing Medical University,
Hypertension Other Ids: University Chongqing, China
2020-02 Phase: Age: Primary Completion:
Study Documents: 18 Years to 100 March 31, 2020
Study Design: Years (Adult,
Cohort April 30, 2020
Sex:
February 17, 2020
Outcome Measures:
•Occupancy rate in the Results First Posted:
intensive care unit (ICU) No Results Posted
•Mechanical Ventilation
Last Update Posted:
•Death
March 17, 2020
•Time from onset of
symptoms to main
outcome and its
components
•Time to Clinical Recovery
- Page 66 of 73 -
Collaborators Type
93 NCT04273763 Evaluating the Efficacy Title Acronym: Enrolling by •Novel Coronavirus •Drug: Bromhexine Study Type: Enrollment: •Second Affiliated •Other Study Start: •The Second AffIliated Hospital
and Safety of Bromhexine invitation Pneumonia Hydrochloride Interventional 60 Hospital of February 16, 2020 of Wenzhou Medical University,
Hydrochloride Tablets Combined Other Ids: Tablets Wenzhou Wenzhou, Zhejiang, China
•2019-nCoV
With Standard Treatment/ 2019NCP1.0 Phase: Age: Medical Primary Completion:
•Drug: Arbidol
Standard Treatment in Patients University
Hydrochloride Not Applicable 18 Years to 80 April 15, 2020
With Suspected and Mild
Granules Years (Adult, •WanBangDe
Novel Coronavirus Pneumonia
Study Design: Older Adult) Pharmaceutical Study Completion:
(COVID-19) •Drug: Recombinant
Group Co.,Ltd.
Human Interferon •Allocation: Randomized April 30, 2020
#2b Spray Sex:
Study Documents: •Intervention Model:
All First Posted:
February 18, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 23, 2020
•Time to clinical recovery
after treatment
•Rate of aggravation
•Clinical remission rate
•Dynamic changes of
oxygenation index
•Time to cure
•rate to cure
•Time to cough remission
•Time to dyspnea remission
•Days of supplemental
oxygenation
•and 6 more
- Page 67 of 73 -
Collaborators Type
94 NCT04303299 Various Combination Title Acronym: Not yet •Coronavirus •Drug: Oral Study Type: Enrollment: •Rajavithi •Other Study Start: •Assistant Professor Subsai
of Protease Inhibitors, THDMS-COVID19 recruiting Infections Interventional 80 Hospital March 15, 2020 Kongsaengdao, Bangkok,
Oseltamivir, Favipiravir, Thailand
•COVID19
and Hydroxychloroquine for Other Ids: Phase: Age: Primary Completion:
Treatment of COVID19 : A
Randomized Control Trial TH-DMS-COVID19 Phase 3 16 Years to 100 October 31, 2020
study Years (Child,
Study Documents:
•Allocation: Randomized November 30, 2020
Sex:
All First Posted:
Assignment
March 11, 2020
Label)
Treatment
Last Update Posted:
Outcome Measures:
March 25, 2020
•SARS-CoV-2 eradication
time
•Number of patient with
Death
•Number of patient with
Recovery adjusted by
initial severity in each arm
•Number of day With
ventilator dependent
adjusted by initial severity
in each arm
•Number of patient
developed Acute
Respiratory Distress
Syndrome After treatment
- Page 68 of 73 -
Collaborators Type
95 NCT04310865 Yinhu Qingwen Granula for the Title Acronym: Not yet •COVID-19 •Drug: Yinhu Study Type: Enrollment: •Zhong Wang •Other Study Start: •Wuhan No.7 Hospital/Jizhong
Treatment of Severe CoVID-19 recruiting Qingwen Granula Interventional 116 March 20, 2020 Energy Fengfeng Group
•Severe Pneumonia •Wuhan
Other Ids: Hospital, Wuhan, Hubei, China
•Drug: Yin Hu Qing Leishenshan
YHQW-Severe- •Chinese Medicine Phase: Age: Primary Completion:
Study Documents: Wen Granula(low Hospital •Wuhan No.7 Hospital/North
V2.0 does) •Phase 2 18 Years and older March 30, 2021 China University of Science
•The First
(Adult, Older and Technology Affiliated
•Other: standard •Phase 3 Affiliated
Adult) Study Completion: Hospital, Wuhan, Hubei, China
medical treatment Hospital of
Study Design: Dalian Medical June 30, 2021 •Zhongnan Hospital of Wuhan
Sex: University University/Tanshan People's
All First Posted: Hospital, Wuhan, Hubei, China
•Tanshan
People's •Wuhan Leishenshan (Thunder
Assignment
Hospital God Mountain) Hospital/The
•Masking: Quadruple Results First Posted: First Affiliated Hospital of
•North China
(Participant, Care Provider, No Results Posted Dalian Medical University,
University of
Investigator, Outcomes Wuhan, Hubei, China
Science and
Technology
•Primary Purpose: Affiliated March 17, 2020
Prevention Hospital
•Jizhong Energy
Outcome Measures: Fengfeng Group
•changes in the ratio Hospital
of PaO2 to FiO2 from
•China Academy
baseline
of Chinese
•PaO2 Medical
Sciences
•blood oxygen saturation
(SpO2)
•clinical status rating on the
7-point ordinal scale
•Time to Clinical
Improvement (TTCI)
•Duration (hours) of non-
invasive mechanical
ventilation or high-flow
nasal catheter oxygen
inhalation use
•Duration (hours) of
invasive mechanical
ventilation use
•Duration (hours) of
extracorporeal membrane
oxygenation (ECMO) use
•Duration (days) of Oxygen
use
•The proportion of the
patients reporting 2019-
nCoV RT-PCR negativity
at Day 10 after treatment
•and 5 more
- Page 69 of 73 -
Collaborators Type
96 NCT04324021 Efficacy and Safety of Title Acronym: Not yet •SARS-CoV-2 •Biological: Study Type: Enrollment: •Swedish Orphan •Industry Study Start: •ASST Spedali Civili di Brescia
Emapalumab and Anakinra in recruiting Emapalumab Interventional 54 Biovitrum March 2020 Dipartimento di Reumatologia
Reducing Hyperinflammation Other Ids: e Immunologia Clinica, Brescia,
•Biological: Anakinra
and Respiratory Distress •Sobi.IMMUNO-101 Phase: Age: Primary Completion: Italy
in Patients With COVID-19
•2020-001167-93 •Phase 2 30 Years to 79 July 2020 •Ospedale Maggiore Policlinico,
Infection.
Years (Adult, Dipartimento di Anestesia-
•Phase 3 Rianimazione e Medicina di
Study Documents: Urgenza, Milano, Italy
Study Design: September 2020
Sex: •Azienda Ospedaliero-
All First Posted: Universitaria di Parma,
•Intervention Model: Parallel Dipartimento di Malattie
March 27, 2020
Assignment infettive ed epatologia, Parma,
Italy
•Masking: None (Open Results First Posted:
Label) No Results Posted •Ospedale Lazzaro Spallanzani,
Dipartimento di Malattie
•Primary Purpose: Infettive ad alta Intensità
di cura ed altamente
March 27, 2020 contagiose,Ospedale Lazzaro
Outcome Measures: Spallanzani, Roma, Italy
•Treatment success
•Time to mechanical
ventilation
•Change from baseline in
Modified Early Warning
system score
resting peripheral capillary
oxygen saturation (SpO2)
partial pressure of oxygen/
fraction of inspired oxygen
(PaO2/FiO2)
•Change of pH in
hemogasanalysis from
baseline
•Change of carbon
dioxide tension (pCO2)
in hemogasanalysis from
baseline
•Change of oxygen tension
(pO2) in hemogasanalysis
from baseline
•Change of potassium in
baseline
•Change of sodium in
baseline
•and 23 more
- Page 70 of 73 -
Collaborators Type
97 NCT04319445 Mindfulness During COVID-19 Title Acronym: Not yet •Migraine Disorders •Behavioral: Study Type: Enrollment: •Wake Forest •Other Study Start:
recruiting Mindfulness Interventional 200 University Health March 2020
•Stress
Other Ids: session(s) Sciences
Study Documents: •Anxiety
IRB00064587 Phase: Age: Primary Completion:
Not Applicable Child, Adult, Older December 2020
Adult
•Intervention Model: Single Sex: December 2020
•Primary Purpose: Other
Outcome Measures: No Results Posted
•Helpfulness of the session
Last Update Posted:
•Platform effectiveness March 24, 2020
•Change in Anxiety Level
•Change in Stress Level
•Value of the session
•Satisfaction with the
session
•Percentage of participants
that showed interest in a
future session
that would recommend
this session to a family
member
by session frequency
preference
98 NCT04319731 A Pilot Study of Human Amniotic Title Acronym: Not yet •SARS CoV-2 •Biological: Human Study Type: Enrollment: •University of •Other Study Start:
Fluid for COVID19 Associated recruiting Infection Amniotic Fluid Interventional 10 Utah March 20, 2020
Respiratory Failure Other Ids:
131618 Phase: Age: Primary Completion:
Study Documents: Early Phase 1 18 Years and older March 20, 2021
(Adult, Older
•Intervention Model: Single March 20, 2021
All First Posted:
•Primary Purpose:
Treatment
No Results Posted
Outcome Measures:
Last Update Posted:
•Ventilator Free Days
March 24, 2020
•Duration of supplemental
oxygen use
•Systemic inflammation
- Page 71 of 73 -
Collaborators Type
99 NCT04321928 Personalized Health Education Title Acronym: Not yet •SARS-CoV-2 •Behavioral: Study Type: Enrollment: •University of •Other Study Start:
Against the Health Damage of PROACTIVE-19 recruiting Personalized health Interventional 7576 Pecs April 1, 2020
•Coronavirus
Novel Coronavirus (COVID-19) education
Outbreak in Hungary Other Ids: •COVID-19 Phase: Age: Primary Completion:
•Behavioral: General
IV/2428- 2 /2020/ •2019-nCoV health education Not Applicable 60 Years and older April 21, 2021
Study Documents: EKU (Adult, Older
•2019nCoV
•Allocation: Randomized August 21, 2021
Sex:
All First Posted:
Assignment
March 25, 2020
•Masking: Double
(Participant, Outcomes
Assessor)
No Results Posted
•Primary Purpose:
Prevention Last Update Posted:
March 27, 2020
Outcome Measures:
•Primary composite rate of
intensive care unit (ICU)
admission, 48 hours of
hospital admission, death
in COVID-19 positive
cases
•The number of general
practitioner visits
•The number of emergency,
hospital admission and
intensive care admission
•Length of hospitalization
and intensive care unit stay
•Organ dysfunction
•Lifestyle changes
•The cost of care
- Page 72 of 73 -
Collaborators Type
100 NCT04270383 Clinical Characteristics and Title Acronym: Not yet •2019-nCoV Study Type: Enrollment: •Beijing •Other Study Start: •Beijing Children's Hospital,,
Long-term Prognosis of 2019- recruiting Observational 500 Children's February 15, 2020 Beijing, China
nCoV Infection in Children Other Ids: Hospital
BCH Lung 012 Phase: Age: •Capital Institute Primary Completion:
Study Documents: up to 18 Years of Pediatrics, December 31, 2020
Study Design: (Child, Adult) China
•Observational Model: •The First Study Completion:
Cohort Sex: Affiliated December 31, 2020
•Time Perspective: All Hospital of
Prospective Anhui Medical First Posted:
University
February 17, 2020
Outcome Measures: •China-Japan
•The cure rate of 2019- Friendship Results First Posted:
nCoV. Hospital No Results Posted
•The improvement rate of •The First
2019-nCoV. Affiliated Last Update Posted:
Hospital February 17, 2020
•The incidence of long-term of Xiamen
adverse outcomes. University
•Duration of fever •Guangzhou
•Duration of respiratory Women and
symptoms Children's
Medical Center
•Shenzhen
•Number of participant(s) Children's
need intensive care Hospital
•Number of participant(s) •First Affiliated
with acute respiratory Hospital of
distress syndrome Guangxi Medical
•Number of participant(s) University
with extra-pulmonary •The Affiliated
complications, including Hospital Of
shock, renal failure, Guizhou Medical
multiple organ failure, University
hemophagocytosis
syndrome, et al. •Hainan People's
Hospital
•Number of participant(s)
who died during the trial •and 13 more
160 additional studies not shown
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services
- Page 73 of 73 -

Search Results

Caricato da

Informazioni sul documento

Titolo originale

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Search Results

Caricato da

Copyright:

Formati disponibili

ClinicalTrials.

gov Search Results 04/01/2020

Study Documents: DAS181-SARS- Phase: Age: •Ansun Primary Completion:

Study Documents: Other Ids: Phase: Age: •OSPEDALE Primary Completion:

Study Documents: KUMC-COVID-19 •Drug: Phase: Age: Primary Completion:

•Time to improvement in •and 47 more

Study Documents: GST-G1 Phase: Age: Primary Completion:

Last Update Posted:

•days on mechanical Last Update Posted:

•Primary Purpose: Last Update Posted:

•Primary Purpose: Last Update Posted:

Study Documents: Other Ids: Phase: Age: Primary Completion:

•Primary Purpose: Last Update Posted:

•Primary Purpose: Last Update Posted:

•Mortality rate from any

•Primary Purpose: Last Update Posted:

Last Update Posted:

Study Documents: CD24Fc-007 Phase 3 18 Years and older May 2021

•Primary Purpose: Last Update Posted:

•The number of days of

•Primary Purpose: Last Update Posted:

•Primary Purpose: Last Update Posted:

Study Documents: GIMI-IRB-20002 Phase: Age: •Shenzhen Primary Completion:

Last Update Posted:

•the length of hospital stay Last Update Posted:

•Absorption of Lung shadow

Last Update Posted:

Study Documents: 2020-02-2 Phase: Age: Primary Completion:

Last Update Posted:

160 additional studies not shown

Potrebbero piacerti anche